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ABSTRACT
“HOPE FOR EVERY ADDICTED AMERICAN”
An Opioid Epidemic in the Age of Ethopolitics:
Implications for U.S. Drug Policy and Governing Problematic Subjects
By
Elizabeth Newcomer
Advisor: Professor Alyson Cole
The United States is in the midst of an unprecedented drug epidemic instigated by
overprescribed pain relievers and cheap, accessible heroin. Beyond its immense scope, what
makes this opioid epidemic distinctive is a widespread awareness of its effects among privileged
populations and a political consensus that it cannot be effectively addressed with existing,
punitive drug policies. Building upon analyses of the drug addict identity and policy change as
well as critical addiction studies, I critically examine the discourses of the opioid epidemic,
considering their impact on U.S. drug policy since 2000 and analyzing the implications of these
changes for governing – in a Foucauldian sense – people labeled drug addicts. I demonstrate that
the epidemic has brought what I term the “normalized sympathetic addict” (or NSA) to the
forefront of public discourse. This empathetic figure is juxtaposed against the “marginalized
threatening addict” (or MTA), the typical menacing drug addict. Focus on the NSA of the opioid
epidemic has lent authority to the discourses of addiction disease and recovery, which are
informed by ethopolitical and advanced liberal governmental logics, making possible novel
modes of government through the “recovering addict” identity. The “progressive” public health
policies inspired by these discourses allegedly offer equal opportunities to both NSAs and MTAs
to engage in recovery. However, I argue that recovery’s individualizing and privatizing logic
enables these policies to perpetuate the discriminatory effects of the War on Drugs by obscuring
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inequalities and displacing blame for biased outcomes onto addicts’ individual choices to accept
or reject recovery. Thus, despite significant changes in discourse inspired by the opioid
epidemic’s NSA, drug policy remains a useful tool for managing problematic subjects through
their identities and maintaining the hegemonic political order, even as it claims to be more
humane and less discriminatory.
Keywords: opioid epidemic; drug policy; addiction recovery; critical addiction studies;
discourse analysis; ethopolitics
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I. INTRODUCTION
According to the Centers for Disease Control and Prevention (CDC), “[t]he United States is
in the midst of a prescription painkiller overdose epidemic” (CDC 2015d). The Department of
Health and Human Services (HHS) calls this overdose epidemic “unprecedented” (HHS 2013),
the Department of Justice (DOJ) calls it a “true national crisis” (Bureau of Justice Assistance
2014), and the Office of National Drug Control Policy (ONDCP) calls prescription drug abuse “a
major public health and public safety crisis” (ONDCP 2011a). Experts and the media
characterize the current opioid epidemic as “the worst drug epidemic in our history” (Sifferlin
2015) a title not unwarranted as the White House reported in 2011 the epidemic had already
killed more people than the two most recent drug epidemics – crack cocaine in the 1980’s and
heroin in the 1970’s – combined (Young 2011).
The opioid epidemic is typically described as originating from systemically overprescribed
prescription opioid pain relievers such as hydrocodone, oxycodone, morphine, and methadone
(CDC 2015b). Partially in response to demands to treat chronic pain, partially the product of
aggressive marketing campaigns by pharmaceutical companies (Bell and Salmon 2009; Hansen
and Roberts 2012; Kolodny et al. 2015); between 1999 and 2013 the number of opioid
prescriptions in the U.S. quadrupled even though the amount of pain reported by the population
did not increase (CDC 2015b). During that same period, opioid-related overdose deaths also
quadrupled killing 16,000 people in 2013, surpassing car crashes as the leading cause of injury
death in the U.S (Ibid). Rates of heroin use – a naturally occurring opioid – have also risen in
recent years as regulatory controls have reduced the availability of prescription opioids (CDC
2015a) and heroin has become cheaper, more potent, and more widely available (Jones et al.
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2015). As a result, heroin overdose rates nearly quadrupled between 2002 and 2013, and nearly
doubled between 2011 and 2013 alone (Jones et al. 2015).
The epidemic first gained media attention in local newspapers in Maine and Ohio in 2000
(Ordway 2000; Whelan and Asbridge 2013). Prescription opioids were nicknamed “hillbilly
heroin” for their prevalence in rural areas in the Northeast, Appalachia, and the South (Tough
2001). However this phenomenon quickly spread nationwide, and prescription drug abuse was
declared a national epidemic in 2011 by the CDC (CDC 2011). That same year the ONDCP
released a four-fold strategy to address the epidemic through education, tracking and monitoring
prescriptions, proper disposal of unused pharmaceuticals, and enforcement (ONDCP 2011a). An
overabundance of opioids in the U.S. – particularly in rural and suburban areas where opioids
were not previously plentiful (Wood 2014) – has triggered a shocking drug epidemic unlike any
other in U.S. history, and policymakers and experts have scrambled to respond. For example,
former West Virginia Representative Nick Rahall (D-WV) stated in a Congressional hearing in
2012, “The toll of destruction and devastation heaped upon America’s families and our economy
by this epidemic demands the United States Congress must act, and act swiftly” (Rahall (WV)
2012, 21). Former Representative Mary Bono Mack (R-CA) echoed this urgency, stating,
“Simply put, we are in the midst of an American tragedy” (Mack (CA) 2012, 22).
Beyond its immense scope, what makes the contemporary opioid epidemic distinctive is an
acute awareness of its effects among privileged socioeconomic and racial groups typically
thought to be insulated from “hard” drug use and associated problems, problems typically
ascribed to urban, poor neighborhoods and people of color. CDC data shows that prescription
overdose deaths are most likely among those ages 25-54, non-Hispanic whites, and men, though
women’s rates of opioid overdose are rising at a faster rate than men’s (CDC 2015f). Heroin use
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and overdose is also most common among young adults age 25-34, non-Hispanic whites, men,
and people living in the Northeast and Midwest (HHS 2015, 3). Although the data shows that
poor, rural, white individuals are the most likely to die from opioid overdoses (CDC 2015e),
much of the public dialogue has focused on rising rates of opioid use and overdose among
middle-class, suburban white people, particularly young people (Achenbach 2014). The opioid
epidemic “cuts across class, race, and demographic characteristics” (Bureau of Justice Assistance
2014), defying stereotypes about drug addiction and demanding a “coordinated...governmentwide response” (ONDCP 2014b, 2).
It is well-established that actual or perceived demographic changes among those using
drugs affects popular and political discourses about drug use and addiction and subsequently
public policy (Acker 2002; Campbell 2000; Cooper 2004; Courtwright 1982; Hickman 2007;
Musto 1987). Dual conceptions of the addict operating in tandem – one sympathetic for the
dominant class, one menacing for the underclasses – have been a consistent feature of the
figurative drug addict (Hickman 2007; Dawn Moore 2007) since the concept’s inception (Reith
2004; Sedgwick 1993). The distinction between the two has historically been based on the
individual’s position in hierarchies of socioeconomics, race, immigration status, gender, and
sexuality (Acker 2002; Campbell 2000; Hickman 2000), and the attributed source of the addict’s
problem, either an illness or an inherent moral or personality flaw (Cooper 2004; Courtwright
1982). Studies of past drug epidemics show that greater public attention to one or the other
construction of the drug addict has contributed to policy changes alternately emphasizing
treatment or incarceration for drug users (Acker 2002; Campbell 2000; Cooper 2004;
Courtwright 1982; Hickman 2007; Musto 1987).
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In this case, public awareness of the opioid epidemic’s impact in middle- and upper-class,
suburban neighborhoods and among white young and middle-aged people has elevated what I
term the “normalized sympathetic addict” (or NSA) to the forefront of drug policy discussions.
This addict is distinguished by their privileged identity and is described as having the capacity to
recover from the disease of addiction through treatment. The NSA is constructed in contrast to
what I term the “marginalized threatening addict” (or MTA) who is distinguished by their
stigmatized identity and their supposed aversion to treatment and recovery. The contemporary
opioid epidemic – the material reality of skyrocketing numbers of people using, overdosing, and
dying from opioids – and the popular and political discourse surrounding the epidemic –
animated by the NSA and the discourse of addiction disease and recovery – are being
strategically deployed to change the tone of U.S. drug policy from a nearly exclusive “War on
Drugs” criminal justice and incarceration approach to a professedly “balanced, compassionate,
and humane” approach that incorporates limited public health interventions without abandoning
traditional law enforcement tactics (ONDCP 2013c, 1). Such public health policies include those
crafted in response to the opioid epidemic such as expanding access to the overdose antidote
naloxone and Medication Assisted Treatment (MAT) like methadone and buprenorphine. Some
of the broader drug policy changes in the last fifteen years have also been influenced by these
discourses, such as removing or reducing mandatory minimum drug sentences, expanding
alternatives to incarceration, and broadening addiction treatment coverage through the
Affordable Care Act (ACA). These policy changes are described as scientifically informed and
evidence-based responses to the public health and safety risks associated with addiction because
they provide treatment for the addict rather than – or in conjunction with – punitive measures,
offering them an opportunity to begin the process of recovery from addiction. Changes in the
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U.S. approach to drug policy since the turn of the century are typically attributed to drug war
fatigue, the pursuit of cheaper alternatives to mass incarceration, a general decline in the crime
rate since the 1990’s, and reduced public concern about drug use (Apuzzo 2014; Desilver 2014;
Gottschalk 2007; Neill 2014; Pew Research Center 2014). These remain important factors but I
find the opioid epidemic and its main character, the normalized sympathetic addict, and the
supporting discourses of addiction as a disease and particularly addiction recovery have also
made critical contributions to these modifications.
Beyond these immediate changes to drug policy, the discourses of the opioid epidemic also
have wider political effects and have altered how addicts are governed – in a Foucauldian sense –
through their identities (Foucault 1981). I investigate these broader implications by conducting a
critical discourse analysis, considering what these discourses generate, allow, and require as well
as what they forbid and render invisible and unspeakable, with a specific focus on how addicts
are further differentiated and governed through the discourse of addiction recovery. I find the
discourses popularized by the opioid epidemic, particularly the ethopolitical discourse of
addiction recovery, advances the objectives of advanced liberal government by compelling
addicted subjects to adopt new modes of behavior under the guidance of experts in order to
reinvent themselves toward ideals of freedom, happiness, and health. In pursuit of these goals,
recovering or potentially recovering addict subjects are rendered governable through their “free”
recovery-consumer choices, choices curated by the state through the regulation of experts and
which ultimately align with the reproduction of the existing political hierarchy (Rose 1999,
2007). The discourse of addiction disease and contemporary legal norms of justice and equality
require that recovery ostensibly be available to all addicts, eradicating past dichotomous
governing strategies for sympathetic and threatening addicts that discriminated against
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subordinated groups. Therefore, recovery makes possible new distinctions among addicts that
crosscut the MTA and NSA identities. Addicts are further distinguished by their status as
recovering addicts, potentially recovering addicts, or addicts refusing to recover, and through
these designations they are more precisely – and allegedly more justly – governed. Indeed, the
policies and practices of recovery do appear to be empowering for some self-identified
recovering addicts who are using this discourse to organize and advocate for their social,
political, and health rights. Recovery also allows some addicts to disassociate from their
stigmatized addict identity and assume a more socially acceptable identity in recovery. However,
the obligation to recover and the addict’s inability to make choices in their own best interest
while in the throes of their addiction also legitimates coercive and punitive tactics to induce
recovery and enforce compliance, justified as being in the addict’s own best interest, even if
applied over their own objections.
Finally, the advanced liberal logic of recovery ignores structural barriers that prevent
marginalized populations from succeeding in recovery and instead attributes failure to individual,
freely made choices to reject a benevolently provided opportunity to reintegrate into society
through recovery. Thus, the political work accomplished by recovery discourse is akin to what
Cole found in contemporary anti-victimist discourse that in its “unremittingly privatizing and
therapeutic” logic thereby “displaces or translates issues of institutional power and social
inequity into matters of character” (Cole 2007, 19). In this case, the discourse of recovery
displaces blame for disparities in the criminal justice and addiction treatment systems from
institutional biases and highly unequal distribution of resources to personal failure, justifying
ostracism and incarceration for the intransigent addict. Thus, professedly progressive drug
policies relieve pressure on the state to provide security and ensure health more equitably by
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individualizing social problems related to drug use, and disguise drug policy’s continued role in
differentiating deviance and reproducing the hegemonic political order through dehumanization
and incarceration.
Structure
I begin by briefly reviewing the existing literature on discourse and drug policy, describing
the approach I take to studying governmental rationalities, subject formation, and discourse
analysis, and defining key terms. In the following section I analyze the discourses of the opioid
epidemic in policy documents, government hearing testimony, statements by advocates and
experts, and media coverage. I identify the NSA’s prevalence in these public narratives, the
supporting discourses of addiction as a disease and addiction recovery, and how these discourses
are employed to further policy change. In the fourth section I review some key changes to U.S.
drug policy in the last fifteen years and identify the discursive role of the NSA, addiction as a
disease, and addiction recovery in shaping and legitimating these changes. I then analyze the
political and governmental implications of these discourses and the policies they animate,
particularly their role in governing subjects through the addict identity, differentiated by their
responsiveness to recovery. I conclude by considering broader implications of this inquiry and
future areas of research.
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II. METHODOLOGY
	
  
This study draws on two main bodies of literature. First, examinations of the drug addict
identity and its role in policy change (Acker 2002; Cooper 2004; Courtwright 1982; Hickman
2007; Musto 1987; Neill 2014), and second, research in the “critical addiction studies” tradition
(Reinarman and Granfield 2015) which analyzes medical, therapeutic, criminal justice, and
political discourses about drug addiction and drug policy’s role in managing deviance and
shaping governable subjects (Bourgois 2000; Bunton 2001; Campbell 2000; Hansen and Roberts
2012; Kaye 2013; David Moore and Fraser 2006; Dawn Moore 2007, 2011; O’Malley and
Valverde 2004; Tiger 2015; Valverde 1998; Vrecko 2010). My approach to these literatures is
informed by Foucauldian studies of government, particularly the works of Nikolas Rose.
The Drug Addict Identity and Policy Change
Systems of domination through differentiation (Gilmore 2002) including racism, sexism,
heterosexism, and capitalism have shaped the drug addict identity throughout the history of U.S.
drug policy. Drug use exceeding social acceptability in the U.S. has been present across all
sociopolitical groups and in order to explain and address drug use among these differently valued
groups, at least two distinct constructions of the drug addict have developed. The primary
subjects of drug addiction discourse, the NSA and the MTA, are the product of interconnected
political, medical, psychological, criminal justice, and public health discourses designed to
differentiate between valued and disposable drug users.
First, what I term the NSA is the constructed figure most often used to describe drug
addicts among the privileged classes. I use the terms normalized and sympathetic to reflect how
the NSA is described as being akin to the ideal advanced liberal political subject and the
dominant social group, and the emotional response this figure is designed to elicit. Their problem
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has long been psychologized or medicalized, at times described as an attempt by respectable
people to cope with the pressures of modern life (Hickman 2000) or simply the physiological
result of an irresponsible doctor establishing an addiction to legal medications in an unsuspecting
victim (Courtwright 1982; Hickman 2000, 2007). The NSA identity has typically been assigned
to members of the dominant classes, middle- or upper-class, educated, straight white men. White
upper-class women have been considered particularly susceptible to addiction because of their
weak disposition but even these privileged women experience more dire social consequences
than men for using drugs, often ostracized as failures of pious womanhood and motherhood
(Campbell 2000; Hickman 2007). Despite their benign disposition, drug use among NSAs still
poses a serious problem for society and policy makers. Addiction among this class has been
framed as a serious threat to racial hegemony and white female purity (Hickman 2007), to
American international dominance and security (Campbell 2000), and to the prevailing political
order. Therefore a range of experts is compelled to intervene in these failing citizens’ lives.
Policies have typically provided treatment for NSAs and exempted them from criminalization
(Acker 2002; Hansen and Roberts 2012; Hickman 2007).
In contemporary discourse the NSA is an individual who without their addiction would
otherwise be part of a dominant social group and would adhere to the requirements of
contemporary political subjectivity. Their problem is understood as a disease, some combination
of a preexisting genetic or neurochemical susceptibility and a biological reaction and physical
dependence to specific addicting substances. They are assigned little blame for having a disease
though they are expected to engage in the process of recovery and adopt a range of stateincentivized and expert-guided “techniques of the self” through which they can be restored from
their diseased state to a healthy one (Foucault 1997; Rose 1999, 245). NSAs are considered
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otherwise good people who want to recover but are mercilessly controlled by their disease.
Fortunately, with the help of experts they can regain their capacity to perform the necessary
functions of good citizenship and go on to lead productive, respectable lives.
In contrast, the MTA is a menacing “Other” against which the dominant social order must
be protected. They are typically depicted as part of maligned sociopolitical groups, the poor and
working-class, immigrants, people of color, women, gender nonconforming people, and sexual
minorities. In the past the MTA was commonly described as having “freely chosen to enter into
the company of degenerates” by using drugs, rather than becoming addicted involuntarily
through physician-prescribed medication (Hickman 2000, 82); or as an ominous minority of
“psychopaths, neurotics, and criminals” that need to be tightly controlled or institutionalized
(Courtwright 1982, 142). Historically these addicts were understood as being incurable because
their drug use was a symptom of innate immorality or fatal character flaws (Acker 2002;
Hickman 2000). However, efforts to medicalize addiction have altered the image of the MTA.
These addicts are no longer strictly pathologized as they were in the past, rather they are
understood to be treatable with expert interventions into their misdirected desires, poor decisionmaking skills, and bad habits (Acker 2002; Hickman 2000). Though the MTA shares a medical
condition with the NSA, the marginalized addict is still less trustworthy than their normalized
counterpart. Unmanaged, they are irrational, dangerous criminals who will do anything to feed
their addiction; but with the right interventions, the threat they pose to society can be neutralized.
This understanding of the MTA grew out of disciplinary concerns in the wake of the politically
tumultuous 1960’s and 1970’s and a simultaneous growing complex of state-funded medical
knowledge about addiction and neurochemistry (Acker 2002; Bourgois 2000; Hansen and
Roberts 2012). Interventions developed for the threatening addict such as methadone
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maintenance treatment were designed to control crime and the spread of disease, and are
accompanied by close state surveillance and social stigma (Ibid). Because the threatening addict
rarely submits willingly to treatment, coercion is often required to keep them motivated to pursue
recovery. Thus therapeutic interventions designed to treat the MTA’s addiction remain
embedded in the criminal justice system despite addiction being described as a disease (Tiger
2015). However, the marginalized addict’s disease is not an excuse for illegal or antisocial
behavior, a tendency Dershowitz derided in The Abuse Excuse (Dershowitz 1994). Their illegal
acts may be described as a result of their disease of addiction but they are no less responsible for
those actions. They are held accountable for their transgressions through the criminal justice
system and are simultaneously compelled to take responsibility for managing their disease
through closely monitored and enforced recovery (Tiger 2015).
Producing MTAs by criminalizing the use of drugs associated with a specific group
delineated by race, ethnicity, or nationality is a common political tactic in the U.S., often in an
attempt to resolve sociopolitical and economic tensions by repressing minorities and alleviating
white fear (Musto 1987). According to Hickman the circular logic of the racialization of drug
addiction operates such that for the privileged subject “to be an addict is to be like” the racialized
Other – that is, to lose race, class, and other privileges – but also that to be a racialized Other is
“to be like an addict” whether or not one uses drugs (Hickman 2000, 72). This logic concludes
that when a racialized Other uses drugs they do so as an expression of their essentialized,
stigmatized identity (Ibid). Therefore even if the MTA’s addiction can be arrested, the racialized
addict’s subjugated condition always makes them more similar to the failing addicted subject
than to the ideal political subject (Ibid). The same is true for women. As Campbell documents,
drug policies have been crafted to target women when their increasing autonomy threatens the
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misogynist sociopolitical order (Campbell 2000). Their alleged dissimilarity to the ideal political
subject also sets them apart and requires them to be more closely managed whether or not they
are identified as a drug addict and even if they successfully end their drug use (Ibid). Therefore
even in recovery the MTA remains a marginalized Other as Hickman described, an individual
whose racialized, gendered, or classed identity makes them always like an addict and therefore
needing to be controlled, either through closely policed recovery or through their other
stigmatized identities. Criminalizing drug use and associating it with marginalized social groups
continues to be used to govern addicts and groups conflated with addicts. For example, Zerai and
Banks document how the demonization of “crack moms” in the 1980s and 1990s drove the drug
policy agenda and how this identity was key to governing women who used drugs specifically
and to scapegoat low-income black women generally for social and political crises (Zerai and
Banks 2002). Thus the MTA and NSA identities are shaped by political, behavioral,
psychological, and medical discourses, practices, and contests; and these identities and their
predominant elements affect public policy.
Studies of past drug epidemics show that immigration patterns, moments of cultural,
economic, or political crisis (Hickman 2007; Zerai and Banks 2002), developments in the
science and treatment of addiction (Courtwright 1982; Hansen and Roberts 2012; Kolodny et al.
2015), changes in the perceived or actual populations of drug users (Cooper 2004; Courtwright
1982) and competing discourse coalitions (Stevens 2007), among other factors, have influenced
the content and context of these binary constructions, their alternating prominence in popular and
political discourse, and thus drug policy. Most recently, Neill analyzed how the perception of
drug addicts has influenced policy outcomes from the earliest attempts to control availability of
narcotics at the turn of the 20th century to the present. Neill finds that since 2000 a range of
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factors have contributed to a more compassionate perception of the drug addict as needing
treatment rather than incarceration including marijuana legalization, relatability of prescription
drug use and abuse, and the clear failure of the War on Drugs (Neill 2014). In relation to the
contemporary opioid epidemic, other scholars have investigated professional discourses,
specifically pain management experts (Bell and Salmon 2009) in comparison with addiction
medicine specialists (Whelan and Asbridge 2013) and how each profession differentiated
between drug addicts and legitimate pain patients. Similarly, Whelan, Asbridge, and Haydt
compared coverage of OxyContin, one prescription opioid intimately connected with the
epidemic, in medical journals and North American newspapers focusing on public depictions of
OxyContin as a “problem drug” or a medication with a legitimate medical purpose (Whelan,
Asbridge, and Haydt 2011). Others have examined public discourses of the epidemic and found a
correlation between popular media coverage of the epidemic and overdose death rates (Dasgupta,
Mandl, and Brownstein 2009) and an overemphasis in local media coverage in Kentucky of
prescription opioids’ connection to crime (Tunnell 2005).
Missing in this burgeoning literature on the discourse of the opioid epidemic is an
investigation of the relationship between the depiction of opioid addicts and contemporary policy
changes, particularly in light of developments in the discourses of addiction disease and
recovery. There has been some public discussion about the connection between the two, such as
at the 2014 Harm Reduction Conference in Baltimore, Maryland. Peter Davidson, a medical
sociologist at the University of California, San Diego, reportedly noted the role the opioid
epidemic and its effects among the middle class have had in furthering a harm reduction agenda
in the U.S., stating “[l]egislators are much more interested in the arguments [made by middleclass parents] than they are in evidence” (Godfrey 2014). Will Godfrey, editor-in-chief of
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Substance.com summarized Davidson’s point: “the experience of opioid-related overdoses across
all layers of US society in recent years has won harm reduction new advocates of the sort – white
and rich – that lawmakers tend to listen to” (Ibid). But to my knowledge the discourse of the
opioid epidemic and its role in policy change and projects of government has yet to be examined.
Governing the Drug Addict
I also build on an extensive literature about drug policy and its role in larger projects of
government (Bourgois 2000; Campbell 2000; Hansen and Roberts 2012; Vrecko 2010),
particularly attempts to reconstitute viable, governable subjects out of drug addicts (Bunton
2001; Donohue and Moore 2009; Kaye 2013; Dawn Moore 2007; Reith 2004), because of the
specific threat drug addiction poses to contemporary norms of subjectivity (O’Malley and
Valverde 2004; Sedgwick 1993; Valverde 1998). I use the term “government” here in the
Foucauldian sense, as in “modes of action, more or less considered or calculated...to structure the
possible field of action of others” (Foucault 1982). Appropriate methods of government are
informed by the prevailing logics of governmentality and political rationality. Modes of
governmentality are the conceptual and practical directives for exercising power upon and
through the population; these overlap and intertwine with political rationalities or the modes of
thought dictating the proper exercise of political sovereignty (Foucault 2007, 2010; Rose,
O’Malley, and Valverde 2006). I find Nikolas Rose’s concepts of ethopolitics and advanced
liberal government most useful in understanding the prevailing logics of contemporary modes of
government.
I refer to Rose’s concept of “ethopolitics,” where the capacities of the population are
managed through “sentiments, beliefs, and values; by acting on [the] ethics” of the subject (Rose
2007, 27). “Techniques of the self” – including personal desires, values, and judgments about
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oneself and who one can become – are aligned with governmental objectives for the orderly
reproduction of the socioeconomic and political order (Rose 1999, 2007, 11). This should not be
misconstrued for some type of totalitarian mind control or a deeply ingrained false
consciousness, but rather as an alignment of the goals of governmentality and self by “bringing
the varied ambitions of political, scientific, philanthropic, and professional authorities into
alignment with the ideals and aspirations of individuals, with the selves each of us want to be”
(Rose 1999, 217).
I also cite Rose’s concept of “advanced liberal” society, an intensified version of traditional
“liberalism” and its constant economic interrogation of the functions of government. Advanced
liberalism informs a state “that will govern without governing ‘society’...by acting on the choices
and self-steering properties of individuals, families, communities and organizations” (Ibid, xxiii).
The state, rather than providing for or directly intervening in society or individuals’ lives, instead
is charged with “create[ing] freedom and those capable of inhabiting it” (Ibid); or creating
ethopolitical subjects who can be governed as autonomous and responsible consumers who,
“through acts of free but responsibilized choice” among the vast – yet not unlimited – options of
“lifestyle” and personal identity expression, are governed through those choices and identities
(Ibid). Therefore the government of persons takes place largely outside of the state’s immediate
purview, in the interactions between ethopolitical subjects and a variety of “experts” with whom
they must consult to inform and guide the choices they are compelled to make (Ibid). This allows
state authorities to “govern at a distance” through “techniques of government that create a
distance between the decisions of formal political institutions and other social actors,”
specifically through the regulation of experts and the shaping of autonomous, “free” choice
(Rose 1996, 53–54).
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Ethopolitics and advanced liberal government thus provide the ideological means through
which the drug addict is known and intervened upon, determining which practices are most
appropriate to achieve desired ends, how the efficacy of those practices should be measured, and
thus the design and implementation of drug policy in order to optimize the qualities of the
population. The discourses about drug addiction are shaped by these rationalities as are the
subjectivities afforded to drug addicts through which they are governed (Dawn Moore 2007).
Therefore, studying how drug addicts are governed is also an inquiry into a specific
manifestation of contemporary governmental and political rationalities.
I consider contemporary drug policy through Rose’s “critical biopolitics of control” which
questions “what are the benefits, what are the dangers, what are [the] gains, and to whom, and
what are the costs and to whom, of strategies of control that seek to identify and govern
biologically risky individuals in the name of public protection?” (Rose 2007, 251). My approach
is also similar to Moore’s in Criminal Artefacts in that I am interested in studying the drug addict
identity in order to “gain important insights into a system whose functioning depends in part on
constituting such figures as problems of order in need of solutions” (Dawn Moore 2007, 2).
Similar critical inquiries into contemporary drug policies, the drug addict identity, and projects
of government include Moore’s Benevolent Watch, an investigation of drug treatment courts and
blended strategies of government (Dawn Moore 2011), and Kaye’s consideration of “therapeutic
communities” and the modes of government employed to rid drug offenders of their “drugs
lifestyle,” making possible new types of docile agency (Kaye 2013, 213). Also Campbell’s
analysis of the long history of U.S. drug policy’s utility in governing women (Campbell 2000)
and Zerai and Banks’ analysis of the “crack mom” and “crack baby” in U.S. drug policy
discourse and these figures’ role in governing low-income Black women during a time of
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economic and social destabilization (Zerai and Banks 2002). Building upon these literatures I
examine the discourses of the opioid epidemic, considering their effects on U.S. drug policy and
discourse since 2000 and the political and governmental implications of the changes provoked by
these discourses. By investigating this case I also seek to contribute broader insight into how
problematic subjects in general are governed in the advanced liberal, ethopolitical era of the
contemporary U.S.
Discourse Analysis
In order to identify the discourse of the opioid epidemic, addiction disease, and addiction
recovery and their political and government effects, I analyze the discourses of the opioid
epidemic and drug policy generally. This includes political, medical, psychological, criminal
justice, and public health discourses used by the media, policy makers, experts, and advocates to
describe the opioid epidemic, the drug addict, the drug addict’s problem, potential solutions to
that problem, and policy responses manifesting those solutions. Specific sources include a
sampling of media coverage – primarily national but also local – of the opioid epidemic since
2000 (gathered by searching “opioid epidemic” everywhere and “opioid” in the headline in Lexis
Nexis and Google News searches of “opioid epidemic”) as well as reviewing landmark articles
referenced by other authors, in other news articles, and by lawmakers. I also searched the
Congressional Record for mentions of the opioid epidemic by lawmakers, experts, officials, and
advocates in committee hearings and floor remarks, and in the language of proposed and passed
bills. I reviewed materials produced by government agencies tasked with addressing the opioid
epidemic and implementing drug policy including the U.S. Department of Justice (DOJ), the
U.S. Department of Health and Human Services (HHS), particularly its subsidiaries the
Substance Abuse and Mental Health Services Administration (SAMHSA), the Centers for
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Disease Control and Prevention (CDC), and the National Institute on Drug Abuse (NIDA), and a
thorough review of materials produced by the Office of National Drug Control Policy (ONDCP).
Finally, I reviewed materials produced by research and advocacy groups including the Drug
Policy Alliance (DPA), the Legal Action Center (LAC), Faces and Voices of Recovery
(FAVOR), and the FED UP! Coalition.
While the governing strategies of ethopolitical and advanced liberal democracies are
concerned with limiting state interference in society, I focus on state policies and discourses as
one point of entry to understand how the state “from a distance” enables both state and non-state
actors to intervene in drug addicts’ lives through the practices of psychology, psychiatry,
biomedicine, neurochemistry, behavioral therapy, criminal justice, and public health. I follow
Campbell’s approach to critical policy analysis that examines “policy-making...as a discursive
practice” which has “material effects that shape the experience and interpretation of addiction”
including the practices of experts operating outside the state (Campbell 2000, 6). This approach
also “‘reads’ public policy for what it can tell us about contemporary political culture” and
“examines the structures of political exclusion, social isolation, and economic marginalization”
manifest in policy that reflect the reigning “governing mentalities” often overlooked in typical
policy analysis (Ibid, 7-8). Thus, I examine how policy discourse shapes strategies of
neutralizing “threatening others” by “governing the ‘known facts’ about them” (Ibid, 14) and in
this case, informing interventions that are simultaneously stigmatizing and compassionate.
Terminology
Finally, a note about terms. I use the term “drug addict” as it is the most commonly used
term to describe a person whose drug use exceeds social acceptability. While the newly revised
Diagnostic and Statistical Manual V (DSM-V) has changed the diagnostic terminology to
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“substance use disorders” of varying levels of severity (SAMHSA 2014b), NIDA still uses the
term addiction, which they consider equivalent to the DSM’s definition of substance use
disorders (NIDA 2014, 5), and in my analysis I found the most commonly used terms remain
“addict” and “addiction.” Since my analysis focuses on the significant of terminology, I am
precise in noting certain organizations or individuals that use the term “substance use disorder”
rather than “addiction” and note patterns of use. NIDA currently defines addiction as:
...a chronic, relapsing brain disease that is characterized by compulsive drug seeking
and use, despite harmful consequences. It is considered a brain disease because drugs
change the brain—they change its structure and how it works. These brain changes
can be long-lasting, and can lead to the harmful behaviors seen in people who abuse
drugs (Ibid, 5).
I also use the term “recovery” – as in recovery from drug addiction – as it is also a commonly
used term in the discourse particularly among advocacy organizations and service providers.
Recovery is defined differently among these parties, but the definition used by the ONDCP
encompasses the most common elements in popular usage:
Recovery is a process of change and growth through which people with substance use
disorders stop using, and reestablish friendships and family ties, build positive social
networks, and become productive and responsible citizens. It is characterized by
health, wellness, a sense of purpose, and productive involvement with family and
community. Recovery can occur at the individual, family, and community levels
(ONDCP n.d.).
Finally, my interest here is not whether drug addiction or recovery are “real” – i.e.
biological, psychological, or behavioral phenomena – but rather to consider the personae
constructed by these terms, the network of experts and interventions targeting these figures, and
the political work they accomplish. I understand drug addiction and recovery as socially
constructed identities that are often imposed upon individuals for purposes of government, while
they are simultaneously identities claimed by some who find them politically or socially useful.
Therefore, the observations and conclusions I make in the following analysis should not be
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construed as dismissing the objectives or experience of groups or individuals claiming these
identities for political or personal reasons. An identity shaped in a context of unequal power
relations is not necessarily or purely a tool of government used to control the individual to which
that identity is applied or claimed. As Foucault astutely noted regarding “madness,” though the
concept was founded in a network of medicalized power relations, “[t]his fact in no way impugns
the scientific validity or the therapeutic effectiveness of psychiatry: It does not endorse
psychiatry, but neither does it invalidate it” (Foucault 1997, 296). I similarly seek to investigate
the “games of truth” and the multidirectional systems of power at work in the novel identities
and practices made possible by recent innovations in the discourse of drug addiction and policy,
without assuming that truth and identity only operate in the interests of unidirectional,
hegemonic power (Ibid).
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III. DISCOURSE ANALYSIS OF THE OPIOID EPIDEMIC
	
  
The opioid epidemic is described primarily through three interconnected discourses that
explain why the epidemic is happening, describe the people it affects, and indicate potential
solutions. These discourses are not only changing popular conceptions of who the drug addict is
– and therefore drug policy as past studies would indicate – they are also intentionally being used
to support progressive policy changes. The first discourse is the NSA described in contrast to the
MTA.
The Normalized Sympathetic Addict and the Marginalized Threatening Addict
First, the main character of the opioid epidemic is the NSA. This figure is the most
commonly referred to by lawmakers, experts, and the media when discussing the epidemic and
proposed policy responses. This character is the typical NSA found in past analyses, usually
white, middle- or upper-class, straight, most often young, usually men but sometimes women. In
this discourse, the NSA/MTA binary is operationalized when the sympathetic addict is described
in relief to the silently assumed image of the threatening addict.
The NSA is described as a “citizen who would not ordinarily be associated with the term
addiction” (Levin (MI) 2000, S9113). They are rarely described as criminals or malicious
individuals but rather as “everyday people” who have become “victims” trapped in “the grips of
addiction” (Portman (OH) 2014, S5701). They are “someone who has hopes and dreams,
someone who at some point made a mistake, and now that mistake threatens those dreams and
often devastates their family” (Ibid, S5702). Their lives are contextualized and relatable; they are
described as an otherwise “good productive citizen” (Bradley 2012, 85), a “fellow American”
(ONDCP 2011b, iii) and a lawmakers’ constituent (Lynch (MA) 2012, H5532; Rogers (KY)
2012a, 17). They are family members, neighbors, and colleagues like any other; including “old
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people, lawyers, doctors, teachers...veterans com[ing] back after protecting us” (Carroll 2014)
and “homemakers, professionals, students, and laborers” (Lynch (MA) 2012, 30).
Every time the NSA of the opioid epidemic is referred to as not the “typical” drug addict or
someone who would not normally be pictured as a “junkie,” the MTA is invoked with all of its
attendant racialized, gendered, and classed connotations. A recent piece by TIME magazine
illustrates the juxtaposition of the sympathetic and the “typical” threatening addict: “This is not a
story about dark alleys and drug dealers. It starts in doctors’ offices with everyday people
seeking relief from pain and suffering” (Calabresi 2015). The binary is also present when the
epidemic is described as failing to “distinguish between socioeconomic lines or gender lines or
geographic lines. It's indiscriminate in its path of destruction” (Rogers (KY) 2012b, H5530), and
when the refrains “addiction does not discriminate” (American Society of Addiction Medicine
2014, 1; Bradley 2012, 86; Lynch (MA) 2012, 30) and addiction is an “equal opportunity illness”
(Samuels and McCaffrey 2015) are invoked by lawmakers, advocates, and the media. These
statements reflect the cultural assumption that addiction usually occurs among marginalized
social groups and not among privileged groups. Statements like this are common and reinforce
the larger narrative that drug use, particularly opioid use, was “once almost exclusively an urban
problem” but is quickly “spreading to small towns and suburbs” (Volkow 2014, 9). It is present
among “every racial, geographical, and socio-economic group” and therefore warrants
widespread concern among lawmakers, experts, and the public (Udall (NM) 2014, 1).
The prevailing, culturally produced image of the crazed criminal drug addict – who is most
likely a poor person of color living in the inner city and who deserves incarceration because of
their obstinacy – makes the NSA figure of the opioid epidemic both possible and necessary. Thus
the NSA only exists in relation to its opposite; without the assumed image of the MTA there
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would be no need to distinguish the sympathetic addict as an otherwise normal person with a
relatable story who has fallen victim to the disease of addiction and whose predicament deserves
a compassionate public response. In this way the focus on the sympathetic addict reinforces the
image of the threatening addict, even when it is unspoken. The fact that the NSA is described as
white, male, upper-class, suburban, and educated, the opposite of that figure – a person of color,
a woman, the poor and working class in urban neighborhoods – are de facto associated with the
MTA, the “typical” addict that the normalized addict is not.
The common narrative of the NSA is that they are introduced to opioids through an injury
or other ailment requiring opioid pain relievers, resulting in a “drug addiction [that] often begins
in our medicine cabinets, rather than on the streets” (Udall (NM) 2014, 1). When the prescription
runs out, this otherwise normal person resorts to seeking out pills on the black market and
“people who would never have dreamed of shooting up, like suburban moms and middle-class
professionals, seek respite from the pain of withdrawal” by intravenously injecting opioid pills or
heroin (Calabresi 2015). These individuals are found all across the country, “primarily outside of
the central city – in the suburbs, and in rural areas. Middle class America, affluent America"
(CBS 2013). A big part of the problem is that prescription opioids are easily abusable, readily
available, and “so very addictive” (Fitz 2015, 58). Most dangerously they “do not carry the social
stigma associated with all other drug abuse” because they are prescribed by a doctor and
assumed to be safe (Bradley 2012, 85). Those most susceptible to opioid abuse are “so-called
naive users in the 35-to-64 age group—mostly baby boomers, with their aching bodies and their
long romance with pharmaceutical chemistry” (Kluger 2010) or “naïve” young people (Potter
2014) who through a doctor’s prescription or typical teenage experimentation get hooked on
drugs much more powerful than they realize (Tough 2001). These pills “quickly turn people
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without any real emotional or physical problems into desperate people suddenly facing life-ordeath struggles” (Mack (CA) 2012, 22). Lawmakers have taken it upon themselves to educate the
public about the opioid epidemic and its sympathetic victims in an effort to promote public
health policy solutions to the crisis. As Representative Stephen Lynch (D-MA) wrote in
submitted testimony to a 2012 House Subcommittee hearing on prescription drug abuse:
There is a misperception about substance abuse that prevents many people from
identifying it as the problem it is. That in turn makes it more difficult to find a real
solution. My colleagues and I are here today to refute that misperception, to
testify that this is not an inner city problem or a problem that affects only those
who have made the wrong choices in life (Lynch (MA) 2012, 29–30).
The effects of the opioid epidemic on valued citizens – described as NSAs – has been the
primary concern voiced by policymakers and experts in the last several years and their stories
animate calls for policy change.
In tandem with the NSA, typical MTAs distinguished by socioeconomic, race, gender, and
sexual identities are still present throughout the discourse of the opioid epidemic; they are not the
central figure, rather they are the Other. The MTA of the opioid epidemic is most often poor,
rural, and white. Rural Appalachian and Rust Belt towns marked by “high unemployment and
low self-esteem” (Reynolds 2015) are “havens for prescription drug abuse” (S. S. Brown (OH)
2011, S6592) that is “shredding the social fabric...creating a Wild West-like anarchy in many
communities” (Mishra 2001). Much of the initial media coverage and public concern about the
epidemic was focused on the criminal, sometimes violent activity of these MTAs (Tough 2001).
This figurative addict is typically poor, bilking Medicaid and the taxpayer by complaining of
false ailments to unscrupulous doctors who “prescribe...opioids like candy” (Murphy (PA) 2015,
10). These addicts frequently “‘doctor shop,’ or seek care from multiple physicians” pretending
to be in pain to get their opioid fix (Sensenbrenner (WI) 2012, 2). They also abuse the treatment
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systems intended to help them, such as MAT, which some addicts use not to support their
recovery but rather to “get a month’s supply of buprenorphine to use whenever they can’t get
heroin. It tides them over, enabling them to remain in their active addiction” (Murphy (PA) 2015,
6). Their behavior can only be changed under threat of force or imprisonment, as Governor Peter
Shumlin described in his 2014 State of the State address as he declared a public health
emergency in Vermont as a result of the opioid epidemic:
...let’s do a better job of convincing drug users who wind up in our criminal
justice system that getting help is a better path than addiction. This too is not easy
work. Drug addicts are the best deniers and the best liars you will ever meet.
Some will do just about anything to continue using. But all the research tells us
that an addict is most accepting of treatment right after the bust (Shumlin (VT)
2014, 6).
The common narratives of MTAs are limited to their immediate problems, their irrationality, and
desperation; their current state is only contextualized to pointedly demonstrate their failure to be
a responsible individual and therefore their stories are typically not relatable to the general public
(Seelye 2013). Threatening addicts, unlike their sympathetic counterparts, pose a violent criminal
threat to their communities and are a drain on common resources (Butterfield 2002; Ordway
2000).
Pregnant women in particular are demonized for their opioid use, and Neonatal Abstinence
Syndrome (NAS), a range of symptoms experienced by newborns exposed to opioids including
“breathing problems, fever, tremors, stiff limbs, difficulty feeding, and preterm birth” (Clark and
Patrick 2015) has reportedly increased threefold over the last decade (ONDCP 2014f, 78). The
all-too-common tactic of displacing the country’s problems onto poor women of color has
resurged with states criminalizing drug use during pregnancy (Zerai and Banks 2002). Punishing
pregnant women for using drugs is justified because of the alleged dire medical effects on their
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fetuses. NIDA warns that some children born with NAS likely “will need educational support in
the classroom to help them overcome what may be subtle deficits in developmental areas such as
behavior, attention, and thinking” and that developmental problems may continue into
adolescence (NIDA 2014, 22). These claims echo the alarmist predictions of so-called “crack
babies” growing up to be violent, dysfunctional adults that were prevalent during the crack
epidemic but have since been debunked (Zerai and Banks 2002). Criminalization is also
described as a necessary deterrent to drug use and motivation for pregnant women to initiate
treatment. For example, Tennessee passed a law in 2014 allowing assault charges to be brought
against a woman whose baby tests positive for drugs, with the caveat that she may not be
charged if she is enrolled in a drug treatment program (Boucher and Gonzalez 2015). Despite the
law’s seemingly treatment-focused intention, health care providers and advocates argue these
laws actually push women away from prenatal care for fear of prosecution (Ibid). These laws
also ignore the fact that most women whose babies experience NAS symptoms are already
receiving MAT – typically methadone or buprenorphine – the medically preferred option for
stabilizing opioid-dependent pregnant women that prevents detox and a potential miscarriage
(Gluck 2015). In contrast with the sympathetic addict of the opioid epidemic whose drug use is
contextualized and whose value to society is assumed, pregnant women who use opioids and
their children are dehumanized in the public discourse. For example, Sullivan County, Tennessee
District Attorney Barry Staubus described his area of the state as “drowning in...these children”
with NAS (Gonzalez 2014), and according to state Representative Terri Lynn Weaver (RLancaster) who sponsored the Tennessee bill, women who use drugs during pregnancy “have no
business being parents” (Ibid). She refuted claims that the bill would push women away from
prenatal care, saying:
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These ladies are not those who would consider going to prenatal care. These are
ladies who are strung out on heroin and cocaine and their only next decision is
how to get their next fix...These ladies are the worst of the worst. Again, I want to
emphasize what they are thinking about, and that is just money for the next high
(Gonzalez and DuBois 2014).
Studies have found that women whose babies experience NAS symptoms are predominantly
white, young, poor, and living in rural areas (Gluck 2015). Media coverage is mixed, depicting
Black, Latina, and white women as mothers with babies who experience NAS (Desiderio 2014;
Gonzalez and DuBois 2014). Babies born with NAS are described as “the youngest victims of
our nation’s battle with the prescription drug epidemic,” victimized by their drug using mothers.
They are also a drain on public resources, as a recent study asserted that the rising number of
infants experiencing NAS from 2000 to 2012 were treated at a cost of “an estimated $1.5 billion
in health care expenditures; 80 percent of that is paid for with Medicaid dollars” (Clark and
Patrick 2015).
Despite renewed interest in criminalizing pregnant women who use drugs, the public
narrative about the opioid epidemic has been focused primarily on the sympathetic addict and
their plight to access treatment in the face of stigma. Stories of threatening addicts are the
assumed and accepted narratives of opioid use, particularly heroin use. Criminalizing MTAs,
such as pregnant women, continues to be an effective method of controlling poor women and
blaming them for social ills such as child behavioral and developmental problems, ballooning
health care costs, and huge deficits for public programs such as Medicaid. These MTAs persist in
the public conversation because they are the assumed figurative drug addict and their stories
reinforce the narrative that “most” drug addicts are threatening, and that the opioid epidemic
requires immediate attention precisely because it defies the typical pattern of drug use and
addiction, posing a real threat to white upper-class hegemony. In order to address the opioid
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epidemic and its privileged victims, new stories are being told to justify policies that treat drug
addicts as people whose lives are valuable and deviate from the traditional War on Drugs
approach. These stories are primarily NSAs who have a disease of addiction and are capable of
recovery.
The Disease of Addiction and Addiction Recovery
Addiction has been characterized by medical experts as a disease for decades. NIDA has
produced research supporting the brain disease model of addiction since the 1970’s (Courtwright
2015). However, the current medical model of addiction as a brain disease and the “emerging
view of addiction as a public health issue” (Lofgren 2011, 802) has gained popularity among
policymakers only in the last several decades (Leshner 1997; McGinty et al. 2015) after
considerable resistance from politicians, the criminal justice establishment, and social scientists
(Courtwright 2015). In this model, the source of addiction is found in a combination of the
individual’s genetic, psychological, neurological, and behavioral functioning. Social and
environmental circumstances are acknowledged as contributing but not determining factors.
Though the disease manifests itself in the brain, it is not an immutable characteristic, therefore
pharmaceutical or behavioral “evidence-based” treatment (NIDA 2014, 25) is available to
remedy the “underlying brain disease” (Leshner 1997) and restore normal functioning.
This understanding of addiction is echoed by all the major federal agencies that deal with
drug use (CDC, SAMHSA, ONDCP) and virtually all mainstream medical and therapeutic
organizations refer to addiction as a “chronic relapsing brain disease” (Leshner 1997).
Normalizing addiction by comparing it to other chronic illnesses is a common strategy used to
promote this concept. Experts regularly compare addiction to relatable chronic illnesses such as
diabetes or heart disease and argue that equitable long-term medical care must be the standard
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treatment for chronic addictions (Chen 2014; Lupkin 2013). If addiction is a disease like any
other, it can likewise be treated and successful recovery is possible. Former Representative
Dennis Kucinich (D-OH) made this clear during his opening statement for a 2010 House
Domestic Policy Subcommittee hearing titled “Treating Addiction as a Disease: The Promise of
Medication-Assisted Recovery.” He stated:
...scientific research definitively shows that addiction is a treatable medical condition.
Like people with any other medical condition, drug-addicted individuals need to have
access to medications to treat the disease” (Kucinich (OH) 2010, 2).
However, addiction is unlike other chronic diseases in that it undermines one’s free will by
“hijacking” the brain and disrupting normal social functioning. Dr. Nora Volkow, Director of
NIDA, described this aspect of addiction in that same hearing:
...[drug addiction] affects fundamental areas of the brain that enable us, for example,
to exert control over our desires and emotion, which explains why a person that is
addicted will compulsively take the drug despite catastrophic consequences to that
person and their family (Volkow 2010, 4).
Dr. Thomas McLellan, then-Deputy Director of ONDCP, also described the effects of drug use
as “ultimately eroding inhibitory control, turning drug-seeking into a compulsion, and erasing
motivation for normally pleasurable human relationships” (McLellan 2010, 3).
Addiction as a brain disease requiring medical treatment factors significantly into the
discourse of the opioid epidemic where there is an immediate need to respond to the public
health crisis of opioid-related deaths. Opioids are one of the few drugs for which medications
have been developed to treat overdoses and dependence, lending itself to an understanding of
opioid addiction as a disease and the normalized sympathetic opioid addict as needing MAT to
support their “long-term recovery” (Botticelli 2014, 11). The argument that MATs support
recovery by addressing the physiological components of the disease of addiction is common. By
“helping individuals start and remain in behavioral therapy and achieve long-term recovery,”
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MAT is a critical element of effective treatment and therefore supported by many lawmakers and
nearly all addiction experts (Kucinich (OH) 2010, 2).
The concept and discourse of addiction recovery also has a long history. Treatments
promising cures for drug addiction emerged along with the addict identity, particularly for NSAs
(Campbell 2000; Courtwright 1982; Hickman 2007). Contemporary addiction recovery discourse
has proliferated from its origins in the modern treatment industry and is gaining mainstream
acceptance as never before, due partially to its promotion by influential governmental agencies,
medical experts, and a novel type of advocacy group. In my analysis of official documents and
legislative history, I found the contemporary language of recovery used by government agencies
goes back at least to the 1990’s when SAMHSA began celebrating “National Alcohol and Drug
Addiction Recovery Month” in 1998 (SAMHSA n.d.). In his 2003 State of the Union (SOTU)
address, former President George W. Bush shared a “message of hope” with all “Americans who
struggle with drug addiction” declaring “the miracle of recovery is possible, and it could be you”
(Bush 2003). The funding the President announced in his SOTU address eventually became the
“Access to Recovery” program, a voucher system to help low-income people access treatment
(ONDCP 2002, 3, 2004, 6). This program marks the initiation of contemporary recovery
language at the ONDCP, and SAMHSA defined recovery for the first time in 2005 (SAMHSA
n.d.).
Among government agencies, SAMHSA and ONDCP lead the recovery narrative. ONDCP
defines recovery for those with a substance use disorder as necessarily ending drug use but also
as an exhaustive personal overhaul of rebuilding, reclaiming, and transforming one’s life.
Because addiction is a loss of personal control, recovery offers the restoration of willpower
whereby addicts can “stop abusing drugs and resume productive lives” (NIDA 2014, 25). It is
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“characterized by health, wellness, a sense of purpose, and productive involvement with family
and community” (ONDCP n.d.) and requires “active involvement in satisfying work and play,
joyful relationships, a healthy body, and a safe living environment” (SAMHSA 2014a).
Recovery is also resuming one’s rightful social and political roles, as recovering addicts are
reintegrated into their community as “responsible parents, neighbors, and citizens” (ONDCP
2011b, 37). According to the mainstream treatment industry both addiction and recovery have
“psychological, social, and spiritual components” which medical treatment alone cannot address
(Seppala 2015, 38). Therefore, according to Dr. Marvin Seppala of the Hazelden Betty Ford
Foundation, the “keys to recovery that last” include efforts to “improve psychosocial
functioning, enrich relationships, and foster a healthier lifestyle” (Ibid).
Though recovery often requires a team of experts including “doctors, physician assistants,
nurses, counselors, social workers, recovery peer support counselors, and other specialists” to
guide the addict in recovery, motivation to recover must come from the addict themselves
(ONDCP 2014f, 19). SAMHSA declares “self-determination and self-direction are the
foundations for recovery” and the addict is charged with “mak[ing] informed choices” about the
treatment they receive in order to “regain control over their lives” (SAMHSA 2012, 4). Thus the
state should not limit the types of treatment available to people with an addiction. According to
Representative Jim Jordan (R-OH), government must “support individual choices in the type of
treatment that is most beneficial” as determined by each individual choosing from a variety of
recovery options (Jordan (OH) 2010, 3). Neither does the state endorse any type of treatment, as
ONDCP asserted in the 2010 National Drug Control Strategy (NDCS), claiming there are
“countless other pathways to recovery” and that it is less important how a person recovers than
the fact that “they have recovered, and their achievements should be celebrated and built upon”
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(ONDCP 2010, 44). The only requirement for treatment is effectiveness. It must be “a reliable
pathway not just to cessation of drug use, but to sustained recovery, meaning a full, healthy, and
responsible life” (Ibid, 8). And it is an undertaking that lasts a lifetime as “services may need to
continue indefinitely, as relapse can be a lifelong risk” (ONDCP 2012b, 1).
Finally, those who have succeeded in their arduous and ongoing journey in recovery must
“share the gift of recovery with others in need” (ONDCP 2011b, 37). According to SAMHSA
one of the key elements required for successful recovery is hope or “the belief that recovery is
real” because it “provides the essential and motivating message of a better future” for the addict
who is just starting on their recovery journey (SAMHSA 2012, 4). ONDCP is particularly
adamant that recovering people be publicly visible so they might “instill hope that recovery is
possible for every American, even those with the most severe cases of addiction” (ONDCP 2010,
44). Therefore recovery from addiction is much more than just stopping drug use or arresting the
disease of addiction, it is the ultimate ethopolitical intervention to reconstruct a responsible,
independent, choice-making citizen out of the broken addict by compelling them to act in the
interest of the person they want to become.
The possibility of recovery for the NSA has been a significant element in the discourse of
the opioid epidemic. Critically, these addicts are capable of recovery as Dr. Harry Chen of the
Vermont Department of Health testified in 2014 at a Senate Judiciary Committee hearing:
I, along with just about every other parent of young adults, know several of their
classmates who were well-adjusted kids with caring parents whose lives were
taken over by the horrors of opiate addiction. Thankfully, nearly all are now in
recovery and doing well (Chen 2014, 2).
Even amid the “death and destruction” of the epidemic there is hope for recovery through which
“people who are able to stop their use of illicit drugs...can return to vibrant and productive lives”
(Westreich 2015, 44, 47). Dr. Andrew Kolodny, an addiction treatment specialist, suggests that
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even for the millions affected by the opioid epidemic “with treatment, sustained remission and
recovery is possible” and those treated can expect to “go on to lead fully productive lives”
(Kolodny 2014, 5). Addictions are “terribly costly. They ruin lives. They ruin communities” and
yet, according to McLellan, “there's hope. There are 20 million people now that label themselves
as being in stable recovery...Treatment ought to lead to recovery, and it can” (McLellan 2010,
12).
Discourse and Policy Advocacy
The popular narratives of the opioid epidemic’s NSA victims, the fact that they have a
disease, and their potential for recovery are being deployed professedly to destigmatize addiction
and treatment, to inspire hope in those with addiction to pursue recovery, and to secure
progressive policy changes that include public health strategies rather than exclusively criminal
justice strategies. Tactics used to reach these goals include changing the language used to refer to
the drug addict, educating the public that addiction is a disease and is treatable, and highlighting
the experiences of those who have successfully recovered. The beneficiary of policy efforts
promoting recovery is often the NSA of the opioid epidemic. Because the sympathetic addict’s
problem is understood as a disease and they are more likely to be considered amenable to
recovery, they are the figure most often invoked in arguments for policy change. This strategic
approach is supported by public opinion data. The authors of a recent poll investigating public
opinion about addiction, mental health, treatment, and recovery bemoan the prevalence of the
MTA figure, or “street drug users in bad economic conditions” often portrayed in the media,
rather than the NSA figure, people “in the suburbs who have become addicted to prescription
painkillers after struggling with chronic pain” or “inspiring stories of people who, with effective
treatment, are able to overcome addiction and live drug-free for many years” (Desmon and
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Morrow 2014). They recommend combatting negative public perceptions about the nature of
addiction and treatment effectiveness by “educat[ing] the public that [mental illness and drug
addiction] are treatable conditions” and thus increasing support for compassionate policy
responses (Ibid).
Government agencies, advocates, and experts seeking to change public opinion and policy
take precisely this approach. ONDCP states the problem and solution as they see it in the 2014
NDCS: “Stigma, rooted in the misperception that a substance use disorder is a personal moral
failing rather than a brain disease, is a major obstacle to drug policy reform” (ONDCP 2014f,
19). Therefore “reducing the stigma surrounding these medical conditions is a particularly
important component of drug policy reform,” a challenge ONDCP is actively working to address
(Ibid, 2). Toward that end, ONDCP dedicated an entire section of the NDCS 2014 to “The
Importance of Language: Reducing the Stigma Surrounding Substance Use Disorders” (Ibid). In
this section they recommend concerted changes to the discourse of addiction, avoiding terms
such as “substance abuser” which “evokes less sympathy” for the individual and instead using
the term “substance use disorder...thereby reducing the stigma” of addiction and “encouraging
these individuals to seek help at an earlier stage in the disease” (Ibid). SAMHSA has also
worked intentionally to change the public discourse about addiction. The agency held a summit
of treatment and recovery experts in 2005 to create the first national consensus on what recovery
is and what recovery-focused treatment should look like, with one of the primary goals being to
develop “new ideas to transform policy, services, and systems toward a recovery-oriented
paradigm” (SAMHSA 2005, 1). Dr. H. Westley Clark, then-Director of SAMHSA’s Center for
Substance Abuse Treatment (CSAT) was quoted in the summit report suggesting “the Federal
government can play a critical role by crafting messages that treatment works, that recovery is
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real and that peers play a critical role in fostering resilience and embodying a message of hope”
(Ibid, 5). SAMHSA has taken on this role by launching a public awareness campaign to educate
the public about recovery as part of their 2011-2014 strategic initiatives (SAMHSA 2011).
Leading medical associations including the American College of Physicians also recognize
the need to change “public perceptions of the drug user” in order to secure public health policies
and greater access to treatment (Kirschner, Ginsburg, and Sulmasy 2014, 11). Submitted
testimony from Dr. Patrice Harris of the American Medical Association (AMA) to a House
Subcommittee hearing on the opioid epidemic read:
Similar to patients in pain, we should not use terms such as ‘addict’ or ‘junkie’ or
‘user’ because these terms carry with them damaging psychological stigma. Patients
who need care are ‘patients,’ and deserve our care and compassion (Harris 2015, 5).
Former Representative Patrick Kennedy (D-RI) made a particularly pointed argument for an
intentional shift in language in a 2010 House hearing. Kennedy argued that the key to changing
policy and securing effective treatment is changing the perception of the drug addict by focusing
on the NSA, specifically the combat veteran. Kennedy recognized that this figure would be
understood as having a disease and needing treatment which would further the goal of securing
research and investment in effective treatments for addiction. He advises:
We shouldn't at all in this hearing be talking about criminal justice, you know, all
of these stigmatized drugs...This has nothing to do with crack addicts in
California driving buses or prisoners in prison. This is about our American heroes
[veterans]. Let's keep it that way. Because, if we do, we can move forward on this
(Kennedy (RI) 2010, 8–9).
In response to Kennedy’s statement, McLellan agreed that Kennedy had “terrific precedent on
your side,” asserting the legal methadone program in the U.S. in the 1960’s-70’s was developed
“to treat the then opiate problems of returning veterans from a foreign war. If that hadn't
happened, there would have been no political will to create that system” (McLellan 2010, 9).
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This exchange demonstrates the power of the NSA and the intentionality exhibited by experts
and policymakers to make the sympathetic addict the face of public health policy change.
In addition to leading its own public awareness campaigns and advocating for shifts in
language, ONDCP is “spreading the promise of recovery across the Nation” (ONDCP 2014f, 3)
by reaching out to, supporting, and promoting the stories of people who identify as being in
recovery from drug addiction. In 2009 ONDCP founded “the first-ever Recovery branch” under
its Office of Demand Reduction in order “to support the 23.5 million Americans in recovery”
(ONDCP n.d.). According to ONDCP this represents “an unprecedented commitment to support
individuals in recovery” and a promise to “continue to support their cause and celebrate their
success” (ONDCP 2013c, 79). The Administration describes this commitment further as:
...working to lift the stigma associated with addiction by partnering with the
recovery community to speak out about their successes and encourage others to
seek treatment; and reviewing and reforming laws and regulations that unfairly
target those with substance use disorders and impede recovery from addiction,
including those laws and regulations that restrict access to housing, employment,
and attaining a driver’s license or student loan (ONDCP 2013a, 3)
Working directly with recovering addicts is a new approach for ONDCP. Recovery has been in
the agency’s vocabulary for at least a decade but bringing public attention to recovery by raising
the visibility of recovering addicts has only been part of their official strategy for the last several
years. ONDCP implores recovering addicts to be the public, living proof to addicts and nonaddicts alike that “recovery is not only possible, but is a positive force that transforms
individuals, families, and communities” (ONDCP n.d.). Politicians have echoed ONDCP’s
reverent tone for recovering addicts such as Representative Paul Tonko (D-NY) speaking at an
Oversight and Investigations hearing in 2015:
The individuals of the addiction recovery community, in my mind, through their
courage, determination, and conviction are truly heroes. Bearing witness to the
joy and rebirth that recovery has brought to their lives leaves me no doubt that
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complete recovery to a substance-free life is, and should be, our goal for every
person who is struggling in the throes of addiction; a disease (Tonko (NY) 2015,
22).
For ONDCP this is not just rhetoric. The newest “Drug Czar” Michael Botticelli, acting
ONDCP director since 2013 and confirmed as director in 2015, identifies publicly as being in
recovery from addiction and directly connects his openness about his recovery with efforts to
change policy and public perceptions of individuals with “substance use disorders.” In his post
on the White House blog announcing his confirmation as director. he proclaimed:
There are millions of people in recovery in the United States leading meaningful,
productive lives full of joy and love and laughter – and I am one of them...I am
open about my recovery not to be self-congratulatory, I am open about my
recovery to change public policy...I hope that many more of the millions of
Americans in recovery like me will also choose to “come out” and to fight to be
treated like anyone else with a chronic disease. By putting faces and voices to the
disease of addiction and the promise of recovery, we can lift the curtain of
conventional wisdom that continues to keep too many of us hidden and without
access to lifesaving treatment. It is time to make a simple, yet courageous
decision to be counted, to be seen and to be heard (Botticelli 2015b).
The New York Times reported on Botticelli’s confirmation noting he “is the first person in
substance-abuse recovery to hold the position” and his identity “far from the liability it once may
have been, is considered evidence that the government is moving toward addressing drug abuse
more through healing than handcuffs” (Schwarz 2015). Botticelli is the ultimate normalized
sympathetic addict in recovery. He has been in recovery for over 25 years, is a white, welleducated man, and he has dedicated his professional life to spreading the promise of recovery
and advocating for other addicts. While it is notable that Botticelli also identifies publicly as a
gay man, not the prototypical normalized addict, his identity remains congruent with
contemporary idealized citizenship rendering him a model homonormative subject (Puar 2007).
In fact, Botticelli compares the stigma faced by those with substance use disorders to that
experienced by LGBT-identified people, and refers to the mainstream LGBT movement’s
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success in “decreasing the shame and stigma surrounding gay folks” by raising their public
visibility and suggests “the substance-abuse field should take cues from the gay rights
movement” and adopt these proven tactics (Schwarz 2015).
Long before Botticelli and ONDCP put out the call to recovering addicts to stand up and be
counted, advocacy groups have been using the discourse of recovery and the recovering addict
identity as organizing principles. The role of one organization in particular – Faces and Voices of
Recovery (FAVOR) – is worth considering at length because of its role in shaping the
ethopolitical discourse of recovery along with ONDCP and others. People who use drugs or who
identify as drug addicts or as being in recovery from addiction are typically “a voiceless, underrepresented constituency" (Ollove 2013). Until recently, addicts lacked the “patient advocacy
groups” formed by those with cancer or AIDS that typically advocate for better treatment and
attempt to destigmatize their illness by speaking out publicly (O’Keeffe 2010, 16). There are
currently a variety of organizations doing policy advocacy and political organizing about drug
use and addiction and they each use different organizing strategies and discourses to support
their work. FAVOR is one of the few groups and the most prominent that explicitly uses the
discourse of addiction recovery to organize and to advocate for addicts’ political, social, and
health care rights.
Founded in 2001, FAVOR is a group “dedicated to organizing and mobilizing the over 20
million Americans in recovery from addiction to alcohol and other drugs” so that they and the
“23 million Americans who have yet to recover” can “lead new lives, free from addiction to
alcohol and other drugs”(FAVOR 2011a). Their work includes organizing the burgeoning “grass
roots social justice movement” of “courageous addiction recovery advocates [who] have come
out of the shadows” (ManyFaces1Voice.org n.d.) and politically empowering recovering addicts
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so they can advocate for federal and state policies that support recovery and remove
“discriminatory barriers” preventing people from recovering or from “moving on to better lives”
once they are in recovery (FAVOR n.d.). One of their primary goals is to change the discourse
about drug addiction including the language used to describe them and the assumed knowledge
about them in order to change public perception and policy. They do so by calling on their
constituents in “long-term recovery” – FAVOR’s poll-tested, preferred terminology – with the
responsibility to speak publicly about their experience in order to break down stigma and to
expand access to treatment for others in, or not yet in, recovery (FAVOR 2013a, 1). For
FAVOR, long-term recovery is abstinence from all drugs and alcohol as well as an opportunity
for drug addicts to “reclaim their lives” (FAVOR 2013b, 6). Even Botticelli uses FAVOR’s
recommended language to describe himself in his official ONDCP biography as being “in longterm recovery from a substance use disorder” (ONDCP n.d.).
According to FAVOR, the visibility and activism of people in recovery are critical to
changing public opinion and public policy because they can demonstrate that recovering addicts
are successful ethopolitical subjects. By sharing their personal stories and working with experts
to produce empirical evidence about addiction recovery, FAVOR demonstrates that treatment
works and people in long-term recovery indeed go on to “lead full, productive, and healthy lives”
(Laudet 2013, 9). For example, FAVOR’s 2013 “Life in Recovery” survey found that “contrary
to the stigmatizing stereotype society has of the individual in active addiction or recovery”
people in recovery experience “dramatic improvements in all areas of life” (Ibid, 1-2). Addicts in
long-term recovery are less likely to be involved in the criminal justice system or contract
infectious diseases and more likely to be positively involved in their families, communities, and
civic duties, to be gainfully employed and financially stable (Ibid). In other words, long-term
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recovering addicts are self-regulating, responsible, and healthy persons who meet the
requirements for advanced liberal citizenship. FAVOR uses this evidence to support their claims
to political, social, and health rights:
...recovery is good not only for the individual, but also for families, communities, and
the nation’s health and economy. The [Life in Recovery Survey] findings emphasize
the call for policies, services, and funding to help more people initiate and sustain
recovery, and for additional research to identify effective and cost-effective recoverypromoting policies and services (Ibid, 2).
All of these discourses – the opioid epidemic and its NSA, addiction as a disease and
addiction recovery – interlock to build a public narrative where political organizing is possible
and policy change is needed. In the next section I demonstrate how these discourses have in fact
animated some recent discursive and material changes in U.S. drug policy.
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IV. U.S. DRUG POLICY IN THE 21ST CENTURY
As described in section II, changes in the demography of drug users, understandings of
drug addiction, and possible solutions to drug addiction have demonstrable effects on policy.
Consistent with previous studies, I find that actual and perceived changes in the typical drug
using population as a result of the opioid epidemic, state and expert understanding of addiction
as a disease, and a growing consensus that recovery from addiction is possible, have likewise had
an effect on U.S. drug policy. Politically powerful groups affected by the opioid epidemic have
pressured the state to take policy actions that prioritize saving the lives of opioid addicts and
providing them with more effective treatment. Public focus on the NSA thus contributed to
forming the political will to embrace the discourses of addiction disease and addiction recovery
because they explain why the opioid epidemic is affecting populations not “typically” subject to
widespread drug abuse and justify changes to drug policies providing these privileged addicts
with opportunities for recovery rather than punishment.
Resulting policy changes include public health approaches that aim to save lives and
prevent the spread of disease as well as demand reduction measures such as treatment and
recovery support services. Of course, these policies are integrated into the predominant War on
Drugs criminal justice approach of supply and demand reduction through law enforcement and
incarceration. Yet, policies with little political clout in the past such as naloxone access and more
accessible and less stigmatized MAT, as well as general policies to expand alternatives to
incarceration (ATIs) and roll back mandatory minimum sentencing have been justified by the
discourses popularized in the contemporary opioid epidemic. For example, Representative
William Keating (D-MA) invoked the NSA when he described the opioid epidemic as crossing
“every social and economic boundary that exists,” forcing Congress and the public to recognize
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that drug addiction is “by no means just a criminal issue..It is, indeed, a public health issue, and
for this reason Congress needs to step in” (Keating (MA) 2012, H5531). Likewise, former
Senator Daniel Moynihan (D-NY) advocated for public health policies in response to the
“chronic, relapsing disease” of addiction when he spoke from the Senate floor in 2000 in support
of expanding access to MAT (Moynihan (NY) 2000, S9113). He went on: “What we are talking
about is not simply a law enforcement problem, to cut the supply; it is a public health problem,
and we need to treat it as such” (Ibid). And finally a letter by Senator Robert Portman (R-OH)
and Senator Tom Udall (D-NM) of the Senate Caucus on International Narcotics Control praised
“hybrid approaches” such as ATIs for “fully integrat[ing] criminal justice with public health” an
appropriate response to the disease of addiction and one that supports recovery (Udall (NM) and
Portman (OH) 2014, 1).
Policies Addressing the Opioid Epidemic
Policy change in response to the opioid epidemic includes dramatically expanding access to
naloxone in the last several years. Naloxone is a drug that can reverse the effects of a deadly
opioid overdose; it is nonabusable and is incredibly effective in reducing mortality rates where
available (DPA 2015b). With increased funding and resources from the federal government,
states have led the way in distributing naloxone widely (Bureau of Justice Assistance 2014). The
Drug Policy Alliance (DPA) reports that 34 states have increased access to naloxone (DPA
2015b), usually by providing training and the antidote to first responders or changing regulations
to allow pharmacists to distribute naloxone directly to opioid users and their friends and family
(DPA 2015d, 2). The DOJ also equipped federal officers with naloxone in 2014, citing the
10,000 overdose reversals enabled by the drug since 2001 and the need for immediate action to
address the “public health crisis” of opioid overdoses (DOJ 2014). The spirit of naloxone
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policies is summed up by Botticelli’s response to a question about naloxone “enabling” opioid
users to continue their addiction, where he declared “[e]very life is worth saving" (DeMio 2015),
refuting the notion that all addicts are unvalued individuals. ONDCP has been a vocal supporter
of increased naloxone access because of its proven effectiveness to save lives and to provide a
point of contact for treatment referral. Numerous politicians have spoken in support of naloxone
access including Representative Michael Burgess (R-TX), medical experts such as Dr. Patrice
Harris of the AMA, and law enforcement including Colonel Thomas L’Esperance of the
Vermont Police Department (Burgess (TX) 2015, 90; Harris 2015, 2; L’Esperance 2014, 3).
Despite the egalitarian rhetoric from Botticelli, there is evidence that NSAs are benefitting most
from naloxone policies. A recent CDC study found “naloxone was most likely to be administered
to women, people between the ages of 20 and 29, and people living in suburban areas” (CDC
2015c). While these results are preliminary, they do indicate that certain types of NSAs – women
and young people living in suburban areas – are more likely to benefit from naloxone expansion
policies than other addicts.
Second, legislation and policy expanding access to MAT has been a recurring theme since
the early days of the epidemic. MAT includes traditional methadone maintenance treatment but
recent efforts have focused on expanding access to buprenorphine, an opioid maintenance
medication that has lower abuse potential than methadone and fewer bureaucratic hurdles
attached to its distribution (Jaffe and O’Keeffe 2003). Expanding access to MAT is praised as an
evidence-based solution to the opioid epidemic by medical experts such as Dr. Harris of the
AMA because it accurately treats addiction as a disease (Harris 2015, 2). It is celebrated by HHS
for saving lives by reducing the risk of overdose and death (HHS 2015, 6) and by the media for
its public health and safety impacts, reducing rates of HIV and Hepatitis C transmission and
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“reduc[ing] crime while enabling addicts to join the workforce and resume their roles within
families” (Ollove 2013). Importantly, MAT can help restore addicts’ free will damaged by
addiction by “enabling opioid-addicted persons to regain control of their health and their lives”
as explained by Dr. Volkow (Volkow 2014, 11). Policies expanding access include the Drug
Addiction Treatment Act of 2000 (DATA 2000) which officially approved buprenorphine for
prescription in private doctor’s offices, making MAT available in some rural and suburban areas
underserved by existing methadone clinics; and DATA 2005, which raised the limit on
buprenorphine patients for physician group practices (R. S. Brown (OH) 2005, H6679).
However, this medication can still be difficult to access in rural areas. Many providers have
extensive waitlists of people who want the medication but cannot find an available provider and
it is much more expensive than methadone making it inaccessible for many without health
insurance. DATA 2000 effectively created bifurcated treatment systems for treating opioid
dependence (Jaffe and O’Keeffe 2003). Methadone clinics are highly regulated and primarily
serve poor, minority, urban, often intravenous heroin users, while buprenorphine prescribers
operate in a more loosely regulated, private system that is integrated into general medicine and
primarily serves middle-class, white, most often opioid painkiller users (Hansen and Roberts
2012). In fact, Hansen and Skinner found that buprenorphine users were “92 percent white, over
half employed at baseline, over half with at least some college education, and 75 percent
prescription opiate addicted” while methadone users were “only 53 percent white, 29 percent
employed at baseline, and 19 percent with some college education, most of whom injected heroin
(Stanton et al. 2006)” (Hansen and Skinner 2012, 176). Once again, the discourse and policy of
the opioid epidemic disproportionately benefit addicts who more closely resemble the NSA than
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the MTA, and medication treatment in particular further differentiates and governs addicts
according to those identities.
Federal and State Drug Policies, Generally
The discourses popularized by the opioid epidemic have also influenced U.S. drug policy
generally. The overall approach to controlling illegal drug use in the U.S. has not changed
dramatically in the last fifteen years as measured by enacted federal funding for supply (58%)
versus demand reduction (42%), which still favors enforcement (ONDCP 2013b, 19). The U.S.
also continues to incarcerate people at the highest rate in the world (ONDCP 2014f, 25), and a
vast network of punitive drug laws remains largely undisturbed beneath new piecemeal public
health drug laws. However, there has been a significant change in the discourse about federal
drug policy. Former ONDCP Director Gil Kerlikowske described the Obama Administration’s
approach in 2012 as “nothing short of a revolution in how we approach drug abuse” (Gardner
2012). More recently, Botticelli described the 2014 NDCS as a collection of policies that “signal
a paradigm shift toward a 21st century drug policy that treats addiction as a disease, not a crime”
(ONDCP 2014d). The NDCS 2014 is described as being explicitly informed by a neuroscientific
understanding of addiction as a disease that can be treated and from which one can recover, a
fact that is “the foundation for the Obama Administration’s drug policy strategy and guides the
Administration’s decision-making on public health and safety” (ONDCP 2014c, 1). It is
described as “restoring balance to U.S. drug-control efforts by coordinating an unprecedented
government-wide public health and public safety approach to reduce drug use and its
consequences” that avoids the extremes of either the War on Drugs or drug legalization (ONDCP
n.d.). The Obama Administration’s approach is restructuring state mechanisms and developing
bodies of knowledge to change drug policy by “aligning criminal justice policies and public
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health systems to divert non-violent drug offenders into treatment instead of jail, funding
scientific research on drug use, and, through the Affordable Care Act, expanding access to
substance abuse treatment” (Ibid). It is an approach based on “science and evidence” (ONDCP
2013b, 7) that “demonstrates a real commitment to a smarter, more humane approach to drug
policy in the 21st century” (ONDCP 2014a). Lawmakers have also voiced support for a “multipronged approach” to drug policy including “law enforcement, treatment, education, and
research” (Rogers (KY) 2012a, 12). Politicians finally appear to be acknowledging that the U.S.
“can’t arrest our way out of this crisis” as Senator Charles Grassley (R-IA) put it in his opening
statement of a Senate Caucus on International Narcotics Control hearing on the opioid epidemic
(Grassley (IA) 2014, 2). The sentiment that drug addiction cannot be effectively addressed by
law enforcement alone has also been echoed by other lawmakers, federal agencies such as the
Drug Enforcement Administration, and multiple District Attorneys in Congressional hearings
and the press (Associated Press 2015; Coffin 2014, 4; Leahy (VT) 2014, 1; Rannazzisi 2014, 4).
Therefore, even though changes have been modest to policy and particularly funding for
the drug war, contemporary drug policy is self-referentially described as radically changing
course because it is informed by the discourses of addiction disease, recovery, and the NSA. The
narrative of a fundamentally new approach to drug policy – without extensively changing policy
– allows politicians, experts, and state agencies to concur with public opinion that the War on
Drugs has failed and claim that new rhetoric, pilot programs, and minimal funding changes
signal they are taking a new approach, while leaving the vast majority of drug laws intact. The
discourse of addiction as a disease conveniently explains why previous policy frameworks failed
and why new interventions will solve the problem of socially unacceptable drug use. Past
policies that responded to drug use solely with incarceration were unsuccessful because they did
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not address the underlying disease of addiction. Now armed with policies that properly blend law
enforcement, treatment, recovery support, and incarceration when necessary, lawmakers and
government agencies can assure the public that the problem will be more effectively addressed.
Though there has been no revolutionary change in drug policy as the rhetoric of ONDCP
and others would suggest, the important changes made to drug policy in the last decade and a
half have been justified at least in part by the three discourses popularized by the opioid
epidemic. These changes include reducing mandatory minimum sentences, expanding
alternatives to incarceration, and revising some policies that discriminate against drug addicts
including expanding treatment coverage through the ACA.
The most significant changes in the traditional drug policy landscape in the last several
decades have been the removal or reduction of mandatory minimum sentences at the federal
level and in at least 29 states across the country since 2000 (Subramanian and Delaney 2014).
Federal sentencing reform passed in 2010 as the Fair Sentencing Act, reducing the infamous
crack/powder cocaine sentencing disparity from 100:1 to 18:1 (ACLU n.d.). In 2013 Attorney
General Holder also changed the DOJ’s policies to avoid charging people accused of low-level,
nonviolent drug offenses with crimes that carry a mandatory minimum sentence (Holder 2013).
These changes have frequently been animated by discourses of justice and racial disparity due to
the demonstrated racial bias in the application of mandatory minimum sentences (DPA 2015c,
1). However, Lofgren found in debates at the state level to reform mandatory minimum
sentences in New York, California, and Arizona, the most frequently cited factors were reducing
state costs for incarceration and drug offenders needing medical treatment rather than
incarceration (Lofgren 2011). Similarly, Attorney General Holder speaking on the federal
sentencing changes in 2013 said of the nearly 100,000 federal inmates incarcerated for drug-
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related crimes “many have substance use disorders” and recommended the objectives of drug
policy should be “deterrence and rehabilitation,” including “diversion programs – such as drug
rehabilitation and community service initiatives” and reentry programs so that “formerly
incarcerated individuals [can] successfully rejoin their communities; [and] become productive
members of society” (Holder 2013). However, these changes do not address the more
fundamental biases in policing and criminal justice practices that cause people of color to be
disproportionately “stopped, searched, arrested, convicted, harshly sentenced and saddled with a
lifetime criminal record” for drug policy violations (DPA 2015c, 1).
The second set of major changes to federal and state policy are exactly what Attorney
General Holder suggested, expanding alternatives to incarceration (ATI) for drug offenders
particularly Drug Treatment Courts (DTCs) and diversion programs. DTCs are the best-known,
best-funded, and most widely available ATI for drug offenders. According to the National
Association of Drug Court Professionals, there are nearly 2,800 drug courts in all 50 states
(NADCP n.d.). These courts reach approximately 120,000 people each year (ONDCP 2013c, 2).
DTCs typically require regular court appearances with a specific DTC judge, random drug
testing, swift punishment for failed drug tests or rule violations, and strict accountability for
progress in areas essential to recovery such as employment, housing, and interpersonal
relationships. The court suspends drug-related charges against the individual pending successful
completion – or “graduation” – from the DTC program, upon which the charges against the
graduate are usually dropped or reduced.
Other ATIs are also gaining popularity across the nation, particularly at the state level. The
DOJ has supported at least 17 states in “direct[ing] funding away from prison construction and
toward evidence-based programs and services” including diversion programs (Holder 2013).
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Innovations at the state level include “pre-trial diversion, the use of risk assessment tools, drug
courts, enhanced probation and parole protocols, the expansion of treatment (including
medication-assisted treatment), and reentry support” (ONDCP 2014e, 25). In addition to these
“enhanced probation”-type programs, there are a few programs based on harm reduction
principles designed to divert people out of the criminal justice system entirely through prebooking diversion, steering them instead to social services. These programs also use the threat of
criminal charges and incarceration to motivate “client” compliance, but importantly they do not
require abstinence or many of the stringent requirements often required in DTCs and intense
probationary programs (Beckett 2014).
ATIs are praised for diverting “nonviolent offenders” out of the criminal justice system,
addressing the offender’s underlying substance use disorder, providing an opportunity for
recovery, reducing recidivism, and being more cost-effective than incarceration (ONDCP drug
policy for the 21st c webpage). Treatment is often the “better and less costly approach” as
Senator Patrick Leahy (D-VT) noted in a Senate Judiciary Committee hearing in 2014 and it
frees up law enforcement resources to focus on more pressing issues by leading to “fewer cases
landing on detectives’ and prosecutors’ desks” (Leahy (VT) 2014, 2). Senator Robert Portman
(R-OH) also cited treatment’s reduced costs to taxpayers as a reason to support DTCs, but just as
importantly, ATIs can lead addicts to “not just get over their addiction and not be committing
crimes but become productive citizens and taxpayers themselves,” contributing to the tax base
rather than drawing from it (Portman (OH) 2014, S5701).
However, ATIs and particularly DTCs are commonly critiqued for “cherry picking” only
nonviolent first-time offenders – typically described as sympathetic addicts – who are less likely
to recidivate than serial offenders (DPA 2011; Tiger 2015). Access to DTCs is also disparate by
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race. According to a 2008 survey, 62% of drug court participants are Caucasian, 21% African
American, and 10% Hispanic or Latino (Szalavitz 2015), despite the well-documented fact that
African Americans and Latinos are disproportionately arrested for drug offenses (DPA 2015c).
Successful graduation rates also favor the privileged, as Kerwin Kaye, a sociologist who studies
drug policy, explained in a recent media article:
The 50 percent who fail [in DTCs] ... are the most disadvantaged, most likely to
be black, the least educated, and the most in need, so it’s a way of allowing more
privileged white people off the hook (Szalavitz 2015).
A final site of general drug policy change is ONDCP’s review and refinement of policies
that discriminate against recovering addicts. These policies “unfairly target those with substance
use disorders and impede recovery from addiction” and therefore must be changed (ONDCP
2013a, 3). Toward this goal, in 2013 ONDCP and the Department of Education developed a
document explaining Federal Student Aid (FAFSA) eligibility for people with drug convictions
including a clarification of the law that allows those who have a prior drug conviction but were
not receiving financial aid at the time they were charged to be eligible for federal aid (ONDCP
2014e, 23). Most substantially, ONDCP has celebrated two recent public health policies that “for
the first time in history – end discrimination against people with substance use disorders” by
requiring health insurance companies to cover addiction treatment as a disease (ONDCP 2013a,
2), claiming the agency’s role implementing these changes as a key part of their work “lifting the
stigma of addiction” and removing barriers to treatment (ONDCP 2012a). These federal policy
changes were the 2008 Mental Health Parity and Addiction Equity Act (MHPAEA) which
requires insurance coverage for substance use disorder and mental health treatment to be
equitable to that provided for general medical care, and the ACA which declared substance use
disorder treatment an “Essential Health Benefit” requiring all health plans in the marketplace to
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cover mental health and substance use disorder treatment and to comply with the parity law
(Beronio et al. 2013, 2). HHS has described these changes as “one of the largest expansions of
mental health and substance use disorder coverage in a generation” (Ibid, 1). However,
disparities in healthcare access persist even as the ACA is implemented, particularly for racial
minorities and poor individuals, and especially in states that did not expand Medicaid (Evans
2015). Media reports also suggest that rules to enforce parity provisions have not yet been
written, allowing limits placed on MAT access by private insurers and some state Medicaid
programs to persist (Ollove 2013). Therefore, without universal health coverage and enforcement
of the parity rule, low-income people continue to be disproportionately denied access to effective
treatment.
Further Policy Implications
The discourses of the NSA, addiction as a disease, and addiction recovery have supported
and made possible numerous policy changes at the local, state, and federal levels. At the same
time they have also precluded discussion of certain policy options and undermined other
approaches to drug policy that do not conform to the current U.S. model.
First, the objective of recovery and the “struggle” of those in recovery are used to
undermine certain drug policies that politicians oppose. For example, the ONDCP opposes drug
legalization because it “runs counter to a public health approach to drug control” and would
“undermine prevention activities, hinder recovery support efforts, and pose a significant health
and safety risk to all Americans, especially our youth” (ONDCP 2011b, 22). This statement
ignores the results of Portugal’s 2001 drug decriminalization policy which did not significantly
increase rates of drug use while successfully increasing rates of treatment and considerably
decreasing new HIV/AIDS cases and drug overdose deaths (DPA 2015a). Marijuana legalization
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also poses a threat to recovery by providing “confusing messages” that “perpetuate the false
notion that marijuana use is harmless” which “hampers the struggle of those recovering from
addiction” (ONDCP 2011b, 21). By this logic, if marijuana is legalized, recovering addicts may
think it is safe for them to use and thus jeopardize their recovery, putting themselves and their
community at risk.
Second, despite many efforts to define recovery broadly, the discourse of recovery often
conflicts with harm reduction approaches that value moderation and mitigation of risk. This
causes many effective harm reduction tactics to be dismissed out of hand because they do not
conform to the idea of recovery as an entire lifestyle overhaul or they are described as sending
the wrong message to addicts that it is acceptable to continue to use drugs rather than recover.
MAT is often criticized in this way, such as Representative Tim Murphy’s (R-PA) mostly
rhetorical question to a panel of experts at a House Oversight and Investigations Subcommittee
meeting in 2015 illustrates:
What should be the aim of treatment for opioid addiction: reduce the intake of
illicit drugs by these individuals to more moderate levels? Or should the aim be to
place patients on a path to detoxification and ultimately a full recovery, ending all
illicit uses and removing the need for lifelong opioid maintenance recovery?
(Murphy (PA) 2015, 9).
In this statement Murphy denigrates harm reduction and distinguishes between “full recovery”
and “opioid maintenance recovery,” a seemingly lesser accomplishment and suboptimal
outcome. His description assumes that “true” recovery is total abstinence and that anything short
of that ideal is unacceptable. Despite overwhelming evidence presented to Murphy at this
hearing that MAT is the most successful treatment for opioid addicts and does not constitute a
“replacement” addiction, his puritanical understanding of recovery was unwavering, a common
attitude among those who define recovery as complete abstinence. Policy allegedly informed by
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science also regularly ignores data supporting several harm reduction policy reforms that could
save lives and stop the spread of disease such as Needle Exchange Programs (NEPs) and
Supervised Injection Facilities (SIFs). While ONDCP has advocated for NEPs because of their
proven public health and safety benefits (ONDCP 2014e, 21), there is currently a federal funding
ban against them, a ban that was briefly lifted in 2010 but reinstated in 2011 by a Republican
dominated Congress (HRI 2011). Some states have moved to provide emergency needle
exchanges in response to specific outbreaks of HIV and Hepatitis C as a result of the opioid
epidemic (Schwarz and Smith 2015), but concerns about encouraging or enabling drug use by
making clean needles available to those who use them has prevailed over effective policy.
Similarly, SIFs – facilities where people can legally inject drugs with sterile equipment under the
supervision of medical staff – have been shown to reduce drug overdose death rates and HIV
transmission rates, promote safe injecting practices, and provide a critical point of contact for
drug using individuals to seek treatment if they want it (DPA 2014, 1). However, no SIFs exist in
the U.S. and the possibility is rarely discussed in the mainstream media much less among
lawmakers or in official ONDCP documents. A final proven harm reduction tactic is stabilizing
opioid addicts by prescribing them heroin or other opioids rather than methadone or
buprenorphine. This approach was successful in Sweden with individuals prescribed heroin
improving their social functioning in areas from criminal activity to employment and
psychological wellbeing more than addicts maintained on methadone or morphine (Bourgois
2000). Unfortunately, providing prescription heroin to opioid dependent people is outside the
realm of consideration for most U.S. policymakers despite evidence that it could address the
issue of inconsistent strengths of illicit heroin, a primary source of opioid overdoses, and thus
reduce the unprecedented rates of opioid-related deaths.
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Finally, U.S. drug policy discourse has international implications, potentially hampering
the spread of effective harm reduction and public health tactics that the U.S. does not support.
The new American approach is already being promoted by the U.S. government as an example
for the world to adopt; at the 2012 World Forum Against Drugs, the U.S. “presented a document
to the international community that sets forth the principles upon which the Administration’s
approach to drug policy is based” including addiction is a disease requiring treatment and
recovery is possible with proper support (ONDCP 2013c, 1). Adopting this view is not an option,
in the NDCS 2013, ONDCP demanded that “all countries must view drug policy as a public
health and public safety issue that requires a modern, evidence-based response” (ONDCP 2013a,
3). U.S. drug policy has set the tone for international drug policy for decades, and it is quite
likely that the global policy climate will continue to reflect the U.S. model rather than adopting
more effective harm reduction and decriminalization policies developed in other countries.
This section has demonstrated that the discourses popularized by the opioid epidemic – the
NSA, addiction as a disease, and addiction recovery – have supported some of the important
adjustments made to U.S. drug policy in the last fifteen years and have inspired a “revolutionary”
change in drug policy discourse. In the next section I consider my final question: What are the
political and governmental implications of these changes?
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V. IMPLICATIONS FOR GOVERNING PROBLEMATIC SUBJECTS
As illustrated in the previous section, drug policy and discourse have demonstrable effects
on how drug addicts are governed. In this case, the discourses popularized by the opioid
epidemic and the policies informed by these discourses further distinguish between and attempt
to more effectively govern addicts through their identity as failing subjects. In other words, the
opioid epidemic, its primary character the NSA, and the popular authority it has provided to the
discourses of addiction disease and recovery have made possible novel variations in the
knowledges and interventions – therapeutic, medical, and criminal justice – applied to people
labeled drug addicts through drug policy.
I find the discourse of recovery in particular provides a set of ethopolitical interventions for
the failing addict subject through which they must remake themselves into advanced liberal
subjects who can be regulated through their freedom (Rose 1999, 2007). By this I mean that
recovery provides the means and an ethical imperative for the addict to act on their own
techniques of the self under the guidance of experts in order to improve themselves toward
culturally specific yet personally valued goals of health, fulfillment, and quality of life (Rose
2007). At the same time, recovery compels the addict to become an autonomous, responsible,
choice-making subject whose individually tailored lifestyle aligns with advanced liberal ideas
about self-regulation and appropriate government from a distance (Ibid, 43). The doctrine of
addiction disease declares the addict’s compulsive use of drugs over pursuits of social norms of
health, happiness, employment, and sociality constitutes a “disease of the will” (Valverde 1998).
The compulsion to freedom in advanced liberal society and the “insufficiently free” will of the
drug addict (Sedgwick 1993, 137) deems them problematic subjects who if untreated threaten the
health of the population by spreading disease, breeding vice and crime, and undermining the
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absolute value of freedom. Though the addict is unable to choose to stop using drugs on their
own, they can choose to submit to the process of recovery and the guidance of experts. Their
willing submission to treatment is the simple yet indispensible key to initiating recovery.
Paradoxically, the discourse of recovery blends medical models of addiction disease with
criminological behaviorism so that the addict’s biomedical disease can only be arrested through
their own active choices to change their behaviors in compliance with directives for recovery
(Tiger 2015). Once the addict has acquiesced to recovery, the tenor of subsequent interventions
is best described by Moore in the context of DTCs as “not deploy[ing] strategies of brute force or
repression nearly as much as they offer ‘opportunities’ for people...to ‘choose to change’” (Dawn
Moore 2007, 10). Thus good drug policies are state-supported but expert-directed interventions
that first convince potentially recovering addicts to submit to treatment and then provide them
with “opportunities” to engage in the ethopolitical project of recovery so they can again be
effectively governed through their freedom (Valverde 1998). Simultaneously, policy must also
be able to quarantine the addict who refuses to recover and therefore cannot be effectively
governed as a free citizen in advanced liberal society.
More than just becoming a typical advanced liberal citizen, the recovering addict must
further remake themselves into a biological citizen (Rose 2007). These are subjects whose
biology is a source of identity and their health is a source of right and responsibility (Ibid).
Through expert knowledge, guidance, and intervention, the biological citizen acts upon
themselves for the betterment of their health and as part of a mandated “ethic of active
citizenship” in advanced liberal democracies (Ibid, 25). The recovering addict must take on
specific techniques of the “care of the self” including constant self-evaluation and selfimprovement in order to optimize their health (Ibid; Foucault 1986). The recovering addict has
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taken responsibility for their biological identity by seeking expert direction to manage their
disease and regain control of their lives and can therefore claim rights to treatment, social
acceptance, and political recognition based on their identity as an active, recovering biological
citizen.
A full recovery characterized by advanced liberal and biological citizenship is the
aspiration for all addicts – both marginalized and normalized – and is professedly offered to all
through drug policies designed to convince potentially recovering addicts to take up this
ethopolitical order. Recovering and potentially recovering statuses crosscut the MTA and NSA
identities, further dividing and distinguishing addicts and allowing more targeted application of
governing methods. Keane (2000) describes the recovering addict as not just “the mirror opposite
of the addict’s pathological and unenlightened being, but the recovering addict is also the
promise of what every addict could become” (Keane 2000, 328). Consequently all addicts are
governed through their potential identities as recovering addicts and biological citizens as well as
through their existing NSA and MTA identities. In the past, normalized and marginalized addicts
were governed through dichotomous strategies and institutions, typically pastoral therapeutic or
medical treatment for the sympathetic addict and disciplinary sanctions or incarceration for the
threatening addict. However, contemporary drug laws must declaratively treat all addicts equally.
In the contemporary discourse both types of addicts are described as having a disease and the
solution to their common problem is recovery, therefore policies encouraging treatment and
rehabilitation must be applied to both types of addicts. Each addict requires a personalized
management strategy to achieve recovery which may include therapeutic, disciplinary, and
repressive techniques. Thus, hybrid drug policies integrating public health and existing criminal
justice approaches can be effectively and allegedly equally offered to both normalized and
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marginalized addicts, those amenable to recovery and those resistant to it, by instituting a
continuum of interventions that can be fluidly applied. These mechanisms blend techniques of
government allowing precise interventions according to the addicts’ amenability to recovery. The
state can offer well-behaved, recovery-minded addicts “opportunities for gainful employment,
housing, and education” while “saving the most resource-intensive programs for those with the
most need and the highest risk of recidivism” or the addicts perceived as most averse to recovery
(ONDCP 2014e, 26). Critically, all addicts are described as having an opportunity to recover
through these policies and as making a choice to accept that opportunity or squander it.
Thus the government of drug addicts in the current advanced liberal regime of crosscutting
identities, egalitarian rhetoric, and blended governmentalities proceeds roughly as follows: The
addict is offered the opportunity to engage in the ethopolitical process of recovery, typically in a
therapeutic or medical setting, under the guidance of state and expert pastoralism and motivated
by the regulatory norm of the successfully recovering addict. Not all addicts are offered the same
opportunity to engage in therapeutic recovery, this is dependent upon the addicts’ perceived
identity and how they encounter the addiction treatment and criminal justice complex, such as
through a doctor, an arrest, the type of arrest, criminal history, etc. For those uninterested,
unqualified, or deemed incapable of these self-directed techniques, punitive disciplinary power
in the criminal justice system is used to deter drug use and enforce recovery. A series of
sanctions and incentives are offered to the addict in a restrictive setting. They can choose to
comply with these directives or not, and if discipline fails to provoke engagement in recovery,
the sovereign power to take life through perpetual incarceration or death are reserved as
motivational last resorts and the ultimate punishment for those who refuse to comply. Illegal
drug use must remain criminalized and addiction treatment embedded in the criminal justice
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system because the threat of incarceration is at times the only sufficient incentive for the addict
to agree to manage their peculiar disease through recovery. Addicts unmoved by ethopolitical
incentives or punitive deterrents are rightfully punished for rejecting recovery for at every step in
this process the addict chooses either to capitulate to recovery or to incur more punishment. If
the threat of incarceration or death fails to persuade the addicted subject to surrender then they
have brought their fate upon themselves.
Blending modes of government is a common strategy for managing difficult subjects, as
Donohue and Moore found in the fluid identities of “offender” and “client” and requisite punitive
and therapeutic methods operating simultaneously and co-constitutively to manage people in the
criminal justice system (Donohue and Moore 2009). Moore also found integrated disciplinary
and pastoral interventions in DTCs (Dawn Moore 2011), and Campbell identified how forced
drug treatment for pregnant women is simultaneously compassionate and coercive (Campbell
2000). The result is a range of governmental powers employed simultaneously through policies
that blend treatment, sanctions, and incarceration, all toward the goal of directing the addict to
adopt ethopolitical technologies of recovery and reshape themselves into a viable advanced
liberal subject.
Political Resistance and Identity Reformation
The political implications of the ethopolitical discourse of recovery and supporting public
health drug policies are two-fold. An optimistic projection is that they could deliver on their
promise and modestly begin to unravel the long history of dichotomous treatment for MTAs and
NSAs. It could provide some addicts who would otherwise have been institutionalized, sterilized,
incarcerated, or killed with access to resources and treatment they may find beneficial. The
discourse of recovery is humanizing and could lead to less stigmatization and reduce social
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isolation for people who use drugs, minimizing the harms otherwise caused by criminalization.
For these reasons virtually all advocacy groups, even the most critical, agree that recent policy
changes, particularly those that take a public health approach, are a significant improvement over
strict criminalization policies (DPA 2011).
Recovery discourse could also help build political power among those labeled addicts who
are inclined to engage in recovery. The logic of biological citizenship requires recovering addicts
to organize and “become political” in order to secure their biological rights to effective
treatments and cures as well as freedom from discrimination based on their biological status
(Rose 2007, 149). This makes it possible to build organizations and perhaps a movement based
on the discourse of recovery for addicts to advocate for rights and recognition (Seelye 2015).
FAVOR is a prime example of this. Addicts who can claim recovery are able to take advantage
of their biological citizenship to advocate for themselves, organize and build political power, and
have an impact on public policies that affect them. If recovery advocates are able to effectively
claim rights for themselves and change drug policy, it is possible those changes could also have
wider benefits for addicts who are not in recovery or people who use drugs who do not identify
as addicts or with recovery.
The discourse of recovery also presents a rare opportunity for someone with a stigmatized
identity to disassociate from it and assume a normalized identity, albeit through very specific
methods and invasive techniques of recovery. Still, the addict can take on a new identity as a
recovering addict through which they can avoid incarceration, reintegrate into society, and reap
some of the benefits of possessing a valued identity. For a group that has been categorically
ostracized and institutionalized for being the antithesis of the ideal subject, being able to claim an
advanced liberal subject position may be an effective strategy for advancing addicts’
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independence and ability to make decisions about their own lives (David Moore and Fraser
2006). In fact, it is an identity some embrace and are feverishly organizing to support. For
example, Kaye found that some addicts enthusiastically claimed new identities afforded by the
narrative of addiction and invasive disciplinary drug treatment practices in therapeutic
communities because acquiescence offered the promise of reintegration into society, an
explanation for past failures, hope for future success, a new type of docile agency enabling lowwage work in the formal economy, and benefits such as job training to assist the addict toward
those promises (Kaye 2013). Kaye recommended social scientists studying projects of
government not dismiss this phenomenon but instead:
...take seriously the ways in which poor people sometimes take the state up on its
offer, such that more than once, individuals I interviewed declared with genuine
feeling, ‘Thank God I was arrested!’ (Ibid, 210).
Kaye’s ethnographic findings exemplify how the discourse of recovery succeeds in its
ethopolitical objective by offering addicts a valuable identity, the pursuit of which aligns with
the goals of advanced liberal government as addicts are governed from a distance through expert
guidance to shape their recovery lifestyles. By following these ethopolitical directives addicts are
– perhaps unknowingly – reproducing the system of government that determined they were
problematic subjects in the first place. However, Bourgois recommends from a “humanitarian
risk reduction perspective” that scholars consider the ways certain drug policies might relieve
suffering otherwise caused by criminalization and incarceration even as these policies are used to
govern subjects and reproduce existing sociopolitical hierarchies (Bourgois 2000, 190).
Likewise, I suggest the identities afforded by those policies be given similar consideration.
Finally, because power is not totalizing or unidirectional (Foucault 2007), people labeled addicts
or recovering addicts can also use those identities for their own purposes, including in opposition
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to the hegemonic order. Each novel identity crafted for the purposes of government offers
possibilities for compliance and resistance (Dawn Moore 2007) and the discourse of recovery
makes it possible for addicts to organize, opening drug policy to new demands and new voices
which may prove to be powerful tools of resistance.
Discursive Preclusions, Requirements, and Biases
At the same time, the discourse of addiction recovery often limits much of what can be said
about experiences of drug use. Recovery discourse requires specific stories of addiction and
recovery, primarily first-person narratives from addicts telling their personal tale of degradation
through addiction and redemption through recovery. Only those who are successfully recovering
are invited to share their stories with the media, politicians, and experts, not those who tried to
recover and failed. While these stories may vary as to how the person came to recovery or what
their recovery looks like, they all require redemption through abstinence and the guidance of
experts and their experience must be named recovery from a biological disease of addiction in
order to “count.” The stories of those who do not experience their drug use as problematic or do
not find themselves needing the techniques of recovery in order to change their drug use are
excluded from the public conversation entirely. Those who have used drugs and did not become
addicted – the vast majority of people who ever use drugs – are also not included. Though
recovery introduces the personal experiences of drug users into the public discourse in a
meaningful way it also limits contributions to those that conform to a preexisting narrative of
recovery. The “known facts” (Campbell 2000, 14) about drug addicts are controlled primarily by
esoteric practices and knowledges of medical, criminal justice, treatment, and recovery experts,
and the personal stories promoted in the discourse must confirm these knowledges.
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The discourse of recovery also precludes any other understanding of drug use and drug
addiction other than social maladaptation and disease. Addiction as a neurobiological disease is
the reigning “style of thought” through which the facts about addicts, treatment, and drug
policies are formed (Vrecko 2010, 62). Public health drug policies aimed to divert people with
drug addictions out of the criminal justice system and into treatment assume that all people who
are arrested or encounter expert-identified “problems” related to their substance use have the
disease of addiction. The only question asked of the drug offender is whether or not they are
ready to embrace recovery, not whether or not their drug use is actually disrupting their life. It
flattens all experiences with drugs to one of disorder and disease, ignoring socioeconomic
inequalities that contribute to drug exposure and drug use as well as any other reason why people
might use drugs, such as for pleasure, recreation, or physical or psychological benefits. It also
claims that ending drug use will necessarily improve the addict’s life circumstances, again
ignoring the many other factors that could explain one’s social, economic, and political
dislocation from mainstream society.
In addition, the successfully recovering addict in these discourses is most often illustrated
as a typical NSA. For example, when Botticelli wrote on the ONDCP blog about the success of
drug courts his featured case was Donovan, a young white man from Kentucky. Botticelli
described Donovan’s story as exemplary of “people who seized the chance to change their lives
for the better when they were given the opportunity” (Botticelli 2015a). Similarly, the successful
recovery stories most often promoted on FAVOR’s website are those of typical NSAs, white,
well-educated individuals from good neighborhoods and families who through recovery have
reclaimed a successful position in society (ONDCP n.d.). Stories of normalized recovering
addicts are also dominant in the media, particularly in coverage of the opioid epidemic. A 2014
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NBC series on the opioid epidemic called “Hooked: A teacher's addiction and the new face of
heroin,” featured the story of Michelle, a teacher, mother, and middle-aged white woman living
in suburban New York who despite her good job and privileged lifestyle succumbed to
prescription opioids and eventually heroin addiction (Carroll 2014). Her recovery also began in a
DTC that “motivated me to continue to do the right thing” and she is now an ideal recovering
biological citizen, making it her life’s work to help other addicts by working on the “Drug Court
Team” for the DTC judge who oversaw her case (Ibid).
A New Binary and the Empty Promise of Recovery
Considering these discursive limits and the strong association between recovering addicts
and NSAs, a more critical reading of the implications of recovery discourse suggests it can also
be used to justify coercion and demonization of those who do not embrace recovery and to
legitimize continued disparities in the criminal justice system. First, in the discourse of addiction
disease and recovery, medical and psychological authorities know the truth of the addict – that
their willpower is damaged by addiction and they need recovery to repair it – more accurately
than the addict knows themselves. As former ONDCP Director Kerlikowske wrote in his closing
remarks to the NDCS 2011, addiction “unlike most diseases” is often “obscured by denial”
therefore treatment may need to take place in “non-traditional settings, such as the criminal
justice system” (ONDCP 2011b, 89). Resistance to treatment is understood as a symptom of the
addict’s irrational disease, therefore coerced treatment is justified as being in the addict’s own
best interest even if they protest. As Valverde explains, the celebration of the freedom of the
recovering addict is easily used “to coerce other alcoholics into locked asylums so that, losing
their freedom, they would be given the opportunity to regain it” (Valverde 1998, 16). Reinarman
and Granfield similarly warn that promoting the discourse of addiction disease is not a uniformly
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effective strategy for changing drug policy because of its tendency to legitimize coercive
practices in the criminal justice system (Reinarman and Granfield 2015). For example, the
Tennessee law criminalizing pregnant women who test positive for drugs was characterized by
local District Attorney Steven Crump as in fact helping women by giving them an incentive to
receive treatment and end their drug use:
I think the women we have charged would say the law was helpful to them. Was
it a hard time in their life? Yes. But ultimately did it lead to better things for them
and their children? Ultimately, I think they'd have to agree to that, too (Boucher
and Gonzalez 2015).
The discourse of disease and denial justifies all types of invasive and punitive interventions into
the drug addict’s life in the name of their future health and wellness in recovery, despite their
initial resistance.
Second, recovery discourse also makes possible a new binary of recovering addicts and
addicts who refuse to recover. Just as the NSA of the opioid epidemic is contrasted with the often
unnamed MTA, so too is the recovering addict often described in relief to its implicit shadow,
the addict that refuses to recover. FAVOR at times distinguishes between individuals based on
“recovery status” and what political and social rights they each deserve (FAVOR 2011b, 1). In
the “Recovery Bill of Rights” FAVOR demands social, political, and health care rights for those
who are “no longer misusing alcohol/other drugs and are on the road to recovery” (FAVOR n.d.).
Elsewhere they describe their work as “aimed at ending the punishment and incarceration of
people for their status as people with histories of addiction” (FAVOR 2012, 7), not necessarily
those with ongoing experiences of addiction or drug use. ONDCP likewise criticizes laws that
inexcusably “make no distinction between the person who continues to use drugs and the person
who is on the pathway to recovery” (ONDCP 2010, 44). The agency suggests these laws should
be “either repealed or modified in a fashion that allows exemption of recovering people from
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their effects” so that “a greater number of addicted individuals in early recovery will succeed in
the long-term goals of becoming healthy and productive members of society” (Ibid). Thus, while
both of these groups claim to be working on behalf of all addicts, at times they characterize the
recovering addict as someone who deserves rights, treatment, and compassion in contrast to their
“Other,” the addict who rejects recovery.
In this binary, the recovering addict is celebrated as a courageous advanced liberal subject
whose determined efforts to recover qualify them for social reintegration, while the addict who
refuses to recover is an indecent, unthinking subject whose obstinacy makes them a true
“anticitizen.” According to Rose, anticitizens are failing subjects who “seem to lack all the selfgoverning capacities that are at the heart of civilized moral agency in an advanced liberal
society” (Rose 2007, 242). They have scorned society’s values and therefore must be purged to
protect those values and the population from their corrupting influence (Rose 2000). Therefore,
anticitizen addicts are not excluded from society because the law discriminates against addicts as
a class, or even against particular classes of addicts, but because those specific individuals chose
to reject the opportunity to recover. The grammar of addiction disease and recovery discourse –
in which objective medical knowledge informs policies providing equal access to evidence-based
treatments and treatment success or failure is the result of individual choice – precludes any
discussion of racism, sexism, classism, or any other systematic discrimination manifested in drug
policy. Addicts are not disciplined, coerced, and imprisoned by virtue of their identity as addicts,
but because they are “intractable individuals unable to govern themselves” (Rose 2007, 249).
These are the individuals from which society must be protected; and in the interests of more
efficiently managing risk within the population, state and expert resources are directed at
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controlling these individuals rather than addicts amenable to recovery who can be taught to
manage themselves (Kaye 2013).
Consequently, the individualizing and privatizing logic of recovery obscures structural
barriers preventing marginalized populations from accessing recovery resources, ignores the
highly uneven distribution of resources to support recovery, and disavows biases in the criminal
justice system. Instead, the discourse of recovery attributes persistent disparities in the criminal
justice system and in access to MAT, naloxone, ATIs, and health care to the individual choices
of addicts to accept or reject recovery. Those who attempt to recover and fail are personally
blamed for not sufficiently committing themselves to recovery, no fault is assigned to frequently
ineffective or inaccessible treatment (Cherkis 2015), as the case of the Tennessee law further
demonstrates. According to the law, women criminalized for drug use during pregnancy can
avoid criminal charges by entering treatment, but the law did not provide additional funding for
treatment centers to accept pregnant or parenting women, a chronically underserved group
(DuBois and Gonzalez 2014). Thus the legislature appeared compassionate and informed by the
discourse of addiction disease while offering poor pregnant women a hollow promise of legal
amnesty through recovery and subjecting them to further surveillance and disciplinary control.
Despite ONDCP’s rhetoric promising “to make our public health and safety policies more
effective and more equitable” (ONDCP 2014e, 79), the NSA and the MTA continue to be
governed through their identities as either valued or maligned individuals (Dawn Moore 2007).
Though both addicts are described as having a disease that needs to be treated, biases against
MTAs and in favor of NSAs persist, particularly regarding their access to treatment and recovery
resources and the perception of their amenability for recovery. By blending methods of
government in hybrid policy mechanisms, the state can appear to be treating all equally while
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distinguishing among addicts based on their NSA or MTA identity and their status in recovery
and applying interventions accordingly. Thus, drug policies can support the ethopolitical project
of recovery for NSAs by allowing private doctors to prescribe buprenorphine, requiring
insurance coverage for treatment, and diverting NSAs from the criminal justice system through
ATIs, while simultaneously operating as a mechanism of control for MTAs by tightly regulating
methadone clinics, failing to ensure adequate access to treatment and lifesaving drugs, and
funding surveillance-heavy ATIs that keep MTAs firmly in the orbit of the carceral state
(Gottschalk 2007). The end result remains that NSAs have disproportionate access to
interventions that include treatment while MTAs are still more likely to receive punitive
sanctions and incarceration. Even without strictly dichotomous institutions and policies, MTAs
are still systematically directed to sites of disciplinary and sovereign power through the biased
practices of the criminal justice, treatment, and recovery complexes. They are no longer
categorically pathologized as essentially irredeemable subjects, rather they are targeted as
individual subjects who have chosen not to adopt the equally accessible practices of recovery. By
rejecting an opportunity to reshape themselves into socially acceptable subjects, they have
essentially chosen to exclude themselves from society and therefore deserve the punishment and
ostracism they suffer.
Furthermore, even if MTAs are able to successfully recover, they continue to be excluded
from sharing equitably in the benefits of mainstream society because of the other stigmatized
identities they are assigned. As Hickman noted, the racialized (or gendered, classed, or
sexualized) “Other” is always “like an addict;” recovery promises integration into mainstream
society but that promise is largely empty in a rigidly stratified social system. There may be some
opportunity for upward mobility, but the full benefits of privileged advanced liberal citizenship
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remain unattainable for most. The disregard for systemic inequalities in recovery discourse may
explain why recovery is so attractive to some addicts, such as those quoted in Kaye’s study, and
why recovery so often fails to deliver on its promise of equal access and true social reintegration.
Thus, while some individuals labeled addicts – typically those who already had access to
resources and privileges – are benefitting from heightened visibility and support for addiction
recovery, others who do not have those privileges are largely excluded from those benefits, and
may be further harmed by the discourse of recovery if deemed anticitizens.
Marginalized groups may also be harmed by recovery discourse as it serves the political
objectives of advanced liberalism by renouncing the state’s responsibility to directly address
social problems. Failure to thrive in advanced liberal society is attributed to individual failure to
make appropriate choices. By this logic the state is not responsible for poverty, insecurity, or
poor health because they result from imprudent, individual choice (Dawn Moore 2007).
Accordingly, in the discourse of recovery, social factors contributing to drug use and addiction
are often minimialized because the solution to the addict’s problem is personal rather than
political. Through treatment some addicts are able to reach previously inaccessible public
benefits, but these are provided as a privilege not a right, and are only provided to enable the
addict to become a free and independent subject. Thus recovery discourse relieves pressure on
the state to provide security and ensure health equitably by displacing responsibility for addiction
– a major source of inequality – onto individual addicts.
It also alleviates the demands put on the state by a privileged sector of the population to
address the effects of the opioid epidemic on their valued group. The opioid epidemic’s main
role in this historical narrative is leading privileged groups to pressure policymakers and experts
to respond to the epidemic with new policy tools, contributing to the current prominence of the
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discourses of addiction disease and recovery. By implementing public health policies that
predominantly serve privileged classes by diverting them from the worst aspects of the criminal
justice system, the burden to more thoroughly change that system is relieved. And, by more
efficiently monitoring and controlling marginalized classes through ATIs and MAT, pressure
from below to address discriminatory drug policies is suppressed at the same time.
Finally, recovery discourse makes possible a new method of executing the drug war and a
novel mode of using incarceration to shape identities and sustain inequality. Drug policy and
practice continue to be used to identify, categorize, build knowledges about, and thus make
governable individuals labeled drug addicts. The discourse of addiction recovery provides new
methods of differentiating more precisely among addicts and thereby more efficiently governing
deviance through the drug addict identity. While U.S. drug policy has not massively changed
since 2000 – despite the insistence of ONDCP and others of a “revolution” in approach – public
health policies integrated into the existing complex of criminal policies provide the veneer of a
more progressive and just method for addressing addiction among all addicts while primarily
serving the privileged. These policies simultaneously mask the continuous, targeted effects of
punitive drug policy on the underclasses (Tiger 2015) and blame the marginalized for their
failure to succeed in a system that is built upon their suppression (Campbell 2000).
Therefore, I find the current arrangement of drug policy inspired by the opioid epidemic
and the discourse of recovery is qualitatively different, though not necessarily less oppressive,
than that employed during the War on Drugs. Rather, these seemingly “progressive” policies
may succeed primarily in allowing the most privileged, sympathetically constructed addicts to
avoid incarceration while simultaneously distracting from the carceral state that continues to
ensnare the most marginalized through racialized, classed, and gendered drug policies. Thus drug
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policy remains a useful tool for managing problematic subjects and perpetuating the effects of
the War on Drugs, even as it claims to be more humane and less discriminatory.
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VI. CONCLUSION
The opioid epidemic and the NSA have changed the discourses about drug addiction in the
U.S. in the 21st century, bringing the discourses of addiction as a neurobiological disease and
addiction recovery into mainstream policy and practice. I have demonstrated that these changes
have contributed to official disavowals of the War on Drugs approach and the incorporation of
public health policies at the state and federal level. Consistent with past findings, a drug
epidemic among a privileged group of addicts has led to change in discourse and thus change in
drug policy, and these new policies reflect contemporary governmental logics. These logics
inform novel methods of governing addicts through their identities, in this case through the
ethopolitics of recovery; and I have argued that this mode of government emphasizing individual
choice and responsibility supports recent policy changes that profess equality and justice, yet
retain past policies’ discriminatory effects.
As Moore and Rose suggest, investigating how risky or problematic subjects are governed
can provide insight into how prevailing modes of governmentality and political rationality
function (Dawn Moore 2007; Rose 2007). In this case, I have identified one set of conditions
under which the advanced liberal state will intervene – or enable experts to intervene – in its
subjects’ lives, indicated characteristics of “good” policy and governmental strategies according
to this model, and suggested the ominous political implications of policies informed by these
logics that profess justice. These findings are particularly important in light of the growing
political consensus that the current system of mass incarceration and punitive drug policy needs
to be reformed. The policies implemented in response to the opioid epidemic suggest what more
extensive policy changes might look like, what discourses might animate them, what
governmental methods they might employ, and what their effects may be for people labeled drug
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addicts or criminals. I recommend that social scientists studying these reforms be acutely aware
of the potentially disparate application of new laws, and if and when disparities are identified, to
bring attention to the hypocrisy of equality discourse that ignores and in fact exacerbates existing
inequalities.
This study also points to further areas of investigation including a more in-depth analysis of
the workings and effects of the recovering/not recovering addict binary, as well as an
examination of the “NAS baby” narrative and how it is used to govern poor women and families.
Ethnographic work with groups using the recovery paradigm to organize and act politically and
with those labeled addicts who do not identify with recovery discourse would also be compelling
areas of research, particularly how recovery discourse politicizes or depoliticizes these
individuals’ experiences. Finally, an analysis of recovery discourse and its role in further
demonizing people labeled criminals who cannot claim an illness at the root of their deviance –
particularly those who sell drugs and “prey” upon the addict’s illness – would be particularly
interesting and relevant to developing policy changes.
The privileged victims of the opioid epidemic and the discourses of addiction disease and
recovery have made it possible for recovery experts to proclaim there is now “hope for every
addicted American” (ONDCP 2010, 35). Hope is a critical element in the political economy of
ethopolitics and can be a powerful technique of government, inspiring problematic subjects to
improve themselves in ways that conform to prevailing norms of subjectivity (Rose 2007). But
hope can also be a revolutionary spark, inciting action and making possible new identities and
ways of being beyond existing norms. My analysis suggests that the hope made possible by the
discourse of recovery tends toward the former, but retains possibility for the latter.
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